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  PARK2 (PARKIN) is an E3 ubiquitin ligase whose dysfunction has been 
associated with the progression of Parkinsonism and human malignancies. 
However, the role of PARK2 in cancer remains to be explored.  
  In this study, I report that PARK2 is frequently deleted and under-expressed in 
human glioma, and low PARK2 expression is associated with poor survival. 
Restoration of PARK2 significantly inhibited glioblastoma cell growth both in 
vitro and in vivo, while depletion of PARK2 promoted cell proliferation. 
Furthermore, PARK2 attenuated both Wnt3a- and EGF-stimulated pathways 
through down-regulating the intracellular level of β-catenin and EGFR. Notably, 
PARK2 physically interacted with both β-catenin and EGFR, and promoted their 
ubiquitination. The growth retardation caused by ectopic PARK2 was fully or 
partially rescued by either β-catenin overexpression or EGF supplement. Finally, 
inspired by these newly identified tumor suppressive functions of PARK2, I tested 
and proved that combination of small-molecule inhibitors targeting both Wnt-β-
catenin and EGFR-AKT pathways synergistically inhibited glioblastoma growth.  
  Together, these findings uncover novel cancer-associated functions of PARK2 
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  Glioblastoma multiforme (GBM) is one of the most aggressive human 
malignancies with median survival less than 15 months [1]. To date, genetic and 
functional studies have identified important signaling transductions in GBM 
including receptor tyrosine kinase and PI3K pathways [2, 3]. In addition, albeit 
not genetically altered, Wnt-β-catenin signaling appears to be important for 
maintenance of chemo/radio-resistant GBM initiating cells [4-6]. However, 
further studies are required to characterize more comprehensively the GBM-
associated network and translate the findings into effective clinical management 
of GBM patients.  
  PARK2 (PARKIN) gene encodes a RING-between-RING (RBR) type E3 
ubiquitin ligase which serves as a RING/HECT hybrid [7, 8]. Many studies have 
revealed a complex regulation of PARK2 activity through multiple intra- and 
inter-molecular interactions [9-12]. The functions of PARK2 have been 
implicated in protein turnover, stress response, mitochondria homeostasis, 
xenophagy [13], metabolism and many other cellular processes regulating cell 
growth and survival. Genetically, PARK2 is associated with the risk of autosomal 
recessive juvenile Parkinson’s disease (ARJPD), leprosy, typhoid and paratyphoid 
fever [14-16]. Somatic inactivation of PARK2 has been reported in various types 
of human cancers, however, the biologic relevance of and molecular events 





1.2 Glioblastoma multiforme 
1.2.1 Classification of gliomas 
  Gliomas account for approximately 80% of all malignant tumors within brain 
and central nervous system [17]. Based on histological features, most gliomas can 
be classified into astrocytomas, oligodendrogliomas, ependymomas, and mixed 
gliomas (oligoastrocytomas). Astrocytomas are the most common form of 
gliomas, making up about 75% of all primary gliomas. Glioblastoma multiforme, 
also known as glioblastoma or Grade IV astrocytoma, are highly aggressive and 
malignant, accounting for about 55% of all primary gliomas and over 70% of 
astrocytomas (Figure 1.1). There are two types of glioblastomas, namely primary 
glioblastoma (de novo) and secondary glioblastoma. Secondary glioblastoma may 
evolve from lower-grade tumors and appears with much lower frequency 
compared to primary glioblastoma.  
 
Figure 1.1 Distribution of primary brain and central nervous system gliomas 






1.2.2 Clinical treatment 
  Generally, GBM is considered as a rare but fatal disease with an annual 
incidence below 3 cases per 100,000 people. Males develop the disease 1.6 times 
more frequently than females [17]. The standard treatments for this disease 
include surgery, radiation, and chemotherapy, and combined treatments are 
usually applied for GBM patients. Due to the diffuse infiltration of tumor cells in 
the normal brain tissues, complete resection can rarely be achieved. Therefore, 
radiotherapy is administrated after brain surgery. However, most cases relapse 
within 8 months [18]. Chemotherapy is widely used for many cancers, but GBM 
responses poorly to most chemotherapy due to poor permeability of the blood-
brain barrier and intrinsic unresponsiveness of the tumor. Temozolomide and 
Gliadel (biodegradable carmustine polymer wafers [19]) are the limited choices of 
chemotherapy drugs for GBM treatment. Unfortunately, these treatments are only 
able to prolong the median survival of patients by about 15 months.    
1.2.3 Genetic pathogenesis  
  The cell of GBM origin and the molecular determinants of GBM malignancy are 
not well understood. As the name implies, gliomas are thought to originate from 
glial cells. However, a growing volume of evidences suggests that astrocytes, 
neurons and neural stem/progenitor cells can all give rise to GBM [20-22].  
  Genomic studies of GBM have revealed the somatic genomic alterations of 
GBM [2, 3, 23]. Many genes (e.g. PTEN, TP53, EGFR, PIK3CA, PIK3R1, NF1, 





significantly mutated. Recurrent gene rearrangements (e.g. FGFR3-TACC3 [24], 
EGFR-SEPT14 and SEC61G-EGFR) were identified to be potentially oncogenic. 
Moreover, major singling pathways altered in GBM include RTK-PI3K/MAPK, 
chromatin modification, p53 and Rb pathways. 
  Molecular subclasses of GBM have been proposed based on genomic 
abnormalities and gene-expression signatures [25, 26]. Generally, four subtypes 
of GBM exist, namely Proneural, Neural, Classical, and Mesenchymal (Figure 
1.2). The Proneural subclass was featured with alterations of PDGFRA, point 
mutations in IDH1 and high expression of genes related to oligodendrocyte 
development, such as OLIG2 and NKX2-2. The Proneural subclass can be further 
divided into G-CIMP and non-G-CIMP subgroups by addition of DNA 
methylation profiles (Figure 1.3) [2]. The Neural subtype was characterized by 
the expression status of neuron markers, including GABRA1, NEFL, SLC12A5 
and SYT1. Regarding the Classical subtype, chromosome 7p11.2 amplification 
(containing EGFR locus), 10q23 deletion, and 9p21.3 deletion (containing 
CDKN2A locus) were observed in over 95% of cases. Meanwhile, high 
expression of genes involving neural stem cell marker (NES), Notch pathway 
(NOTCH3, JAG1 and LFNG) as well as Hedgehog pathway (GAS, GLI2 and SMO) 
were observed. Finally, the Mesenchymal subtype was typified by the focal 
hemizygous deletions of 17q11.2 (NF1), co-mutations of NF1 and PTEN, and the 
expression of genes involving mesenchymal markers (e.g. YKL40, MET, CD44 





TNFRSF1A and TRADD). GBMs of Classical or Mesenchymal subtype trend to 
have greater response to Temozolomide and radiation treatment. 
Figure 1.2 Gene expression-based molecular classification of GBM (Figure 
from [26]). Subtype predictions and gene clustering using (A) 173 TCGA GBM 






Figure 1.3 Genomic alterations associated with five molecular subtypes of 
GBM (Figure from [2]). Expression and DNA methylation profiles were used to 
classify 332 GBMs with exome sequencing and DNA copy number analysis.  
1.3 Expression, structure and regulation of PARK2 
  PARK2 is ubiquitously expressed [27]. The transcription of PARK2 can be 
regulated by N-myc, Max, p53 and ATF4 [28-30], and various environmental 
stimulations, such like nutrients, growth signals, mitochondrial and ER stresses 
[30-34]. PARK2 precursor transcripts can be processed by pre-mRNA splicing 
factors, TDP-43 and FUS/TLS [35, 36]. Alternative splicing of PARK2 produces 
multiple tissue-specific variants [27, 37]. Interestingly, PARK2 open reading 
frame (ORF) contains an internal in-frame Kozak sequence which initiates the 
alternative translation of ΔUBL PARK2 [38].  
  PARK2 protein is well conserved from nematodes to humans. Full-length 
PARK2 consists of five important domains, UBL, RING0 (also known as Unique 
PARKIN domain, UPD), RING1, in-between-RING (IBR) domain and RING2. 
Additionally, it contains a class II PDZ domain-binding motif towards the C-
terminal end [39], and a newly identified Repressor of PARKIN (REP, also 
known as tether) fragment between IBR and RING2 [11, 12] (Figures 1.4A-B).  
Structural studies reveal an auto-inhibited conformation of PARK2 through 
complex intra-molecular interactions [9-12]. Briefly, the UBL domain binds to the 
linker region between IBR and RING2 to stabilize the quaternary structure of 
PARK2. REP associates with RING1 at the E2 binding site to block E2 
recruitment. RING0 intervenes between RING1 and RING2 and buries the 





ester formation (Figure 1.4C). Thus, the activation of PARK2 requires massive 
conformational changes, and the intrinsic auto-inhibition of PARK2 implicates its 
strict regulation and important function.   
 
Figure 1.4 Schematic and spatial illustrations of PARK2 structure. A, 
Functional domains of PARK2 protein. B, Structure of full-length PARK2 (PDB 
4K95). C, Surface representation of full-length PARK2 (remodeling of PDB 
4K95) indicating complex intra-molecular interactions and buried catalytic C431. 
 
  The E3 ligase function of PARK2 can be modulated by various mechanisms. 
Phosphorylation (S65), oligomerization, ligand and/or E2 binding contribute to 





(Y143) and Cdk5 (S131) attenuate its activity [41-43] (Figure 1.5). Additionally, 
phosphorylation of PARK2 may modulate its folding, solubility, and ligand or 
substrate binding affinity [44-46]. To date, post-translational modifications and 
interacting partners of PARK2 have been extensively studied [47]. However, the 
mechanism of PARK2 activation, how PARK2 transits between active and 
inactive modes, and what determines the specificity of substrate recognition by 
PARK2 remain largely unclear.  
 
Figure 1.5 PARK2 is regulated by phosphorylation. Sites of PARK2 
phosphorylated by various kinases including PINK1, c-Abl, Cdk5 and CK1.  
 
1.4 Inactivation of PARK2 in cancer 
1.4.1 Mutation 
  Mutations of PARK2 gene occur in both ARJPD and solid tumors. Based on the 
analysis of recent next generation sequencing data via cBio [48, 49], the 
frequency of PARK2 mutations are relatively high in cervical cancer (5.6%), lung 
squamous cell cancer (5.6%), colorectal cancer (2.4%~5.6%), gastric cancer 
(4.6%), skin cutaneous melanoma (3.5%), lung adenocarcinoma (2.7%~3.1%), 





PARK2 mutations have been identified (Appendix 1). Notably, several sites 
mapping to various domains are recurrently mutated, such like A46, T173, T240, 
P294, P343, and E395 (see details in Chapter 3). The biological consequences of 
those mutations need further clarification.  
1.4.2 Copy number alterations 
  Loss of heterozygosity and copy number loss of PARK2 are found in breast 
cancer [27], clear cell renal cell carcinoma (ccRCC) [50], esophageal 
adenocarcinoma [51], glioma [52, 53], non-small cell lung cancer [54], lung 
adenocarcinoma [55], ovarian cancer [27] and pancreatic adenocarcinoma [56] 
(Table 1). Further analysis based on recent cancer genomic studies reveals that 
PARK2 deletion is also prevalent in adenoid cystic carcinoma (10%), skin 
cutaneous melanoma (3.5%), ovarian cancer (3.2%) [48, 49], gastric cancer [57] 
and triple-negative breast cancer (6%) [58], suggesting that copy number loss is 
another leading genomic defect of PARK2.  
1.4.3 Promoter hypermethylation 
  Promoter hypermethylation is a common epigenetic mechanism to alter gene 
expression. PARK2 promoter hypermethylation has been found in acute 
lymphoblastic leukemia (ALL, 26%), chronic myeloid leukemia (CML, 3%) [59], 
and colorectal cancer (4.7%) [60]. 5-Aza treatment could restore the expression of 
PARK2 in ALL cell lines with PARK2 promoter aberrant methylation. 
Interestingly, among 10 samples of CML with lymphoid blast crisis, two showed 





pathogenesis of leukemia remains unexplored. Although the frequency of PARK2 
promoter hypermethylation is low when compared with mutation or deletion, it 
may serve as an alternative way to inactivate PARK2. 
1.4.4 mRNA/protein aberrant expression 
  As a result of genomic and epigenetic inactivation, the mRNA expression of 
PARK2 is down-regulated in a wide spectrum of human malignancies (Table 1). 
Notably, low transcription of PARK2 correlates with increased lymph node 
metastasis, higher tumor grade, and worse overall survival in ccRCC [61]. 
  In parallel to decreased PARK2 mRNA expression, PARK2 protein has been 
shown to be down-regulated in a panel of cancer cell lines [27, 53, 60, 62-65] and 
primary tumors (Table 1) [56, 61, 65, 66]. In pancreatic cancer, PARK2 
expression is negatively correlated with grade and lymph node metastasis [56]. In 
breast cancer, PARK2 levels can predict the outcome of paclitaxel treatment [67]. 
Interestingly, stromal PARK2 abundance is remarkably reduced in malignant 
breast tissues [62], suggesting a potential role of PARK2 in the tumor 
microenvironment. 
  Aberrant or alternative splicing may also lead to PARK2 abnormal expression. 
Aberrant transcripts have been identified in ovarian cancer (15%)  [27], colorectal 
cancer (42%)  [34], and several CML or cancer derived cell lines [59, 64, 68], 
which may result in the disruption of PARK2 ORF and protein function.  
 12 
Table 1 Summary of PARK2 lesions in human malignancies 
Type of lesions Type of malignancies (percentage of cases with PARK2 lesions) Methods References 
Mutation 
Colorectal cancer (1.2%~2.3%); glioblastoma (9.3%); lung cancer1 (6.5%) Sanger sequencing/NGS [53, 60] 
Cervical cancer (5.6%); endometrioid cancer (2.1%);  
lung squamous cell cancer (5.6%); colorectal cancer (2.4%~5.6%); gastric cancer (4.6%);  
skin cutaneous melanoma (3.5%); lung adenocarcinoma (2.7%~3.1%) 
NGS cBio [48, 49] 
mRNA down-regulation 
Breast cancer2; clear cell renal cell carcinoma (52.1%~57%); glioblastoma (61%);  
pancreatic adenocarcinoma (100%) qRT-PCR 
[50, 52, 56, 61, 
62] 
Acute lymphoblastic leukemia2; breast cancer (94.4%); chronic myeloid leukemia 2; non-small 
cell lung cancer (55%); ovarian cancer (46.7%~50%) Semi-qRT-PCR [27, 54, 59, 68] 
Bladder urothelial cancer2; breast cancer2, clear cell renal cell carcinoma2; endometrioid cancer2; 
head and neck squamous cell carcinoma2; lung adenocarcinoma2, thyroid cancer2 cDNA microarray cBio [48, 49] 
Breast cancer2; colorectal cancer2 RNA-sequencing cBio [48, 49] 
mRNA up-regulation Clear cell renal cell carcinoma (10.6%); non-small cell lung cancer (11%); ovarian cancer (10%) Semi-qRT-PCR [27, 54, 61] 
Protein down-regulation 
Hepatocellular carcinoma (83.3%); ovarian cancer (71.4%); glioma2 WB [64, 65, 69] 
Breast cancer (stromal tissue) (100%); breast cancer (13%); clear cell renal cell carcinoma 
(82.8%); pancreatic adenocarcinoma (76%) IHC [56, 61, 62, 66] 
Promoter hypermethylation Acute lymphoblastic leukemia (26%); chronic myeloid leukemia (3%); colorectal cancer (4.7%) MSP [59, 60] 
Gene breakage Breast cancer (6%) FISH [66] 
Loss of heterozygosity Breast cancer2; non-small cell lung cancer2; ovarian cancer2 MSM [27, 54, 68] 
Copy number loss 
Pancreatic adenocarcinoma (100%) qPCR [56] 
Colorectal cancer (33%) array-CGH [60] 
Clear cell renal cell carcinoma (27%); colorectal cancer (24.4%); esophageal adenocarcinoma2; 
glioblastoma (24.5%~29.1%); gastric cancer2; lung adenocarcinoma (11.6%); triple-negative 
breast cancer (6%) 
SNP chip [50-53, 55, 57, 58] 
Adenoid cystic carcinoma3 (10%); skin cutaneous melanoma (3.5%); ovarian cancer (3.2%) SNP chip/NGS cBio [48, 49] 
Abnormal splicing Colorectal cancer (42%); ovarian cancer (15%) RT-PCR [27, 34] 
1The detailed subtype was not clear. 2The exact percentage was not revealed, or could not be calculated. 3The percentage was 
estimated on the basis of NGS data. Abbreviations: FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; MSM, 
microsatellite marker analysis; MSP, methylation specific PCR; NGS, next-generation sequencing; SNP, single nucleotide 






  Together, genetic and epigenetic disruptions of PARK2 are prevalent across 
human malignancies, suggesting that PARK2 inactivation may enhance neoplastic 
transformation and progression. 
1.5 PARK2 and tumorigenesis in animal models 
  Animal models have helped to investigate the role of PARK2 in tumorigenesis. 
To date, seven lines of Park2 knockout mice have been generated in an attempt to 
reproduce Parkinson’s disease [70-76]. Generally, Park2-/- mice develop normally, 
and do not show severe neurodegeneration phenotype or obvious clinical defects 
[77].  
  However, Park2-/- mice are more susceptible to γ-irradiation-induced 
tumorigenesis [29].  After irradiation, Park2 is specifically elevated in mouse 
spleen and thymus in a p53-dependent manner. Park2-/- mice show significantly 
shorter latency to develop γ-irradiation-induced tumors compared with wild type 
littermates, even though the tumor spectrum is similar (with the predominant type 
being lymphoma).  
  Adult Park2 null mice show reduced body weight but enlarged livers compared 
to wild type mice [78]. Notably, Park2-/- mice develop spontaneous hepatocellular 
carcinoma (HCC) at an advanced age [78]. Those tumors histologically 
recapitulate human HCC with prominent expression of α-fetoprotein and β-
catenin. In mouse liver, Park2 is a lipid-responsive gene whose expression 





metabolism [33]. Whether the dysfunction of liver metabolism contributes to 
subsequent hepatocellular carcinogenesis in Park2-/- mice is unclear.  
  Park2 deficiency also promotes colorectal adenoma development [60]. Park2+/-; 
Apc+/min mice show higher incidence (4-fold increase) of adenomas, and earlier 
onset of intestinal neoplasia compared with Park2+/+; Apc+/min littermates. The 
wild type allele of Park2 is retained in most adenomas derived from Park2+/-; 
Apc+/min mice, suggesting that Park2 may be a haploinsufficient tumor suppressor.  
  Notably, only aged Park2-/- mice develop liver cancer (72 weeks or older) [78], 
and Park2+/-; Apc+/+ mice do not develop intestinal adenoma [60], suggesting that 
Park2 deficiency alone may not be sufficient to drive rapid neoplastic 
transformation. Since PARK2 is critical for mitophagy (selective autophagy to 
degrade damaged mitochondria [79-81]), liver-specific spontaneous tumor 
formation in Park2 null mice may result from the long-term toxic effect of 
mitophagy and/or autophagy defects. A similar phenotype is observed in both 
Becn1+/- and Atg5f/f; CAG-Cre mice [82-84].  
1.6 Involvement of PARK2 in cancer associated signaling pathways 
1.6.1 Microtubule organization 
  Microtubules are critical for diverse cellular processes and have been targeted 
for cancer therapy for decades. The microtubule filaments are composed of α- and 
β-tubulin heterodimers. PARK2 co-localizes with microtubules and possesses 
three independent microtubule/tubulin binding domains, including RING0 





promotes the polymerization of microtubules, thereby increasing their 
stabilization in cooperation with paclitaxel treatment. In response to microtubule-
depolymerizing drugs, PARK2 also suppresses the subsequent activation of 
microtubule-associated protein kinases (MAPKs) including JNK, ERK, and p38 
[86]. Ectopic expression of PARK2 sensitizes breast cancer cell lines to paclitaxel, 
docetaxel and epothilone B. Moreover, PARK2 level correlates with the paclitaxel 
sensitivity in primary breast cancer cells and predicts the response of paclitaxel 
treatment in breast cancer [67].  
  On the other hand, PARK2 also acts as an E3 ligase of α/β-tubulins [87]. 
Interestingly, all of three microtubule/tubulin binding domains and several E3 
ligase-deficient PARK2 mutants are able to rescue the microtubule 
depolymerizing effect by colchicine [85], suggesting that the microtubule-
stabilizing ability of PARK2 is independent of its E3 ligase activity. Further, 
expression of any one of these three domains is sufficient to attenuate the 
activation of MAPKs upon colchicine and nocodazole treatment [86]. Regarding 
how PARK2 balances between microtubule stabilization and tubulin degradation, 
one explanation might be that PARK2 predominantly binds with microtubules and 
selectively targets misfolded tubulins for proteasomal degradation, similar to the 
case of DJ-1 [88, 89].  
  Together, the aforementioned observations suggest that PARK2 is an important 
regulator of tubulin polymerization and microtubule stability. As the dynamics of 





negatively regulate cancer cell metastasis through its microtubule-stabilizing 
activity.  
1.6.2 Cell cycle progression 
  PARK2 appears to play a role in cell cycle progression. A recent study revealed 
the dynamic subcellular localization of PARK2 during cell cycle progression: in 
interphase, PARK2 shows perinuclear distribution; in mitotic phase, PARK2 
mainly localizes to centrosomes and mitotic spindles; and PARK2 is found at 
midbody during cytokinesis [56].  
  Functionally, PARK2 mediates the ubiquitination and degradation of Cyclin E in 
complex with FBXW7 and Cullin1 [34, 53, 92]. It also down-regulates Cyclin D1 
level partially through indirect transcriptional repression [63]. Recent study also 
suggested that PARK2 could form a new class of Cullin-RING-containing 
ubiquitin ligase complex containing FBX4, CUL-1 and α-β-crystallin to target 
Cyclin D1 for degradation [93]. Thus, PARK2 seems to coordinate multiple 
layers of regulatory mechanisms to restrict Cyclin D1 level. Overexpression of 
PARK2 increases G1-phase arrest and delays mitotic entry [62, 63]. Interestingly, 
PARK2 up-regulates the mRNA level of CDK6 specifically in MCF7 breast 
cancer cells leading to the cell cycle arrest and growth suppression [62], 
suggesting that PARK2 may function in a cell-type specific or context-dependent 
manner. 
  PARK2 depletion increases the cell fraction in S and G2-M phase [53]. Multiple 





spindle partially through interaction with γ-tubulin, a protein with well-
established function in nucleation and orientation of microtubules [94-96]. The 
PARK2/γ-tubulin complexes are physiologically present in the cytosol, and 
PARK2 is reversibly recruited to the centrosome through HDAC6, suggesting a 
potential role of PARK2 in centrosome function. As centrosomes contribute to the 
formation of the mitotic spindle, the inactivation of PARK2 in cancer may 
promote the dysregulation of cell division. Indeed, knockdown of endogenous 
PARK2 leads to spindle misorientation [56], and development of multipolar 
spindles as well as micronucleus [53]. Similarly, cells with exogenous C-terminal 
truncation of PARK2 display increased ability to bypass the mitotic arrest induced 
by nocodazole and show a higher frequency of multinucleation [96], suggesting a 
defect in spindle assembly checkpoint. In addition, PARK2 may help to maintain 
the bipolar spindle assembly through transcriptional repression of Eg5 [56, 97], 
thereby facilitating the proper chromosome segregation during cell division. 
Together, PARK2 safeguards the proper mitosis by ensuring the function and 
organization of centrosome and spindle, and PARK2 loss may contribute to the 
development of aneuploidy.  
1.6.3 Mitochondria homeostasis 
  Mitochondria are critical for cell metabolism and cell death whose dysfunction 
contributes directly to cancer development. Increasing amount of evidence 





  Mitochondrial genome. PARK2 binds to mitochondrial DNA (mtDNA), 
enhances TFAM-mediated mitochondrial transcription and restores the PGC-1α 
expression, thereby promoting mitochondria biogenesis [98-100]. Moreover, it 
protects the mitochondrial genome from reactive oxygen species (ROS)-induced 
damage, and supports mtDNA recovery [99]. Long-term overexpression of 
PARK2 selectively eliminates mitochondria with deleterious mtDNA mutations, 
thereby enriching the wild type mtDNA for normal mitochondrial function [101]. 
This suggests that PARK2 is important for the maintenance of integrity of the 
mitochondrial genome, and thus linking PARK2 alterations to tumorigenesis 
[102-104].  
  Mitophagy. The role of PARK2 in the induction and progression of mitophagy 
has been extensively studied, leading to some controversy [79-81]. Generally, 
mitochondrial stress (depolarization) blocks the inner mitochondrial import of 
PINK1 (PTEN induced putative kinase 1) and triggers its auto-phosphorylation 
and stabilization [105-107]. The accumulated PINK1 phosphorylates many 
substrates including Ubiquitin at S65 and PARK2 UBL domain at S65, thereby 
unlocking the auto-inhibition of PARK2, stimulating its self-association and then 
recruiting it to depolarized mitochondrial membrane [40, 108-112] (Figure 1.6). 
Upon activation, PARK2 rapidly catalyzes the ubiquitination of a vast array of 
mitochondrial proteins, such as FIS1, MFN1/2, RHOT1/2, and TOMM70A [80, 
113, 114], and separates mitochondria from the microtubule network [115]. The 
bulky ubiquitination of mitochondrial proteome subsequently recruits adaptor 





Ultimately, PARK2-dependent mitophagy selectively degrades damaged 
mitochondria, thereby maintaining a healthy population of mitochondria.   
 
Figure 1.6 Model of PARK2 activation by PINK1-mediated phosphorylation 
of ubiquitin and PARK2 UBL domain (Figure from [120])  
  The function of mitochondria is often impaired in cancer [121]. Those 
mitochondria isolated from the brain of Park2-/- mice have reduced respiratory 
capacity [122], suggesting that PARK2 loss undermines the mitochondrial energy 
production. However, to what extent PARK2 inactivation contributes to the 
mitochondria impairment in cancer remains uncertain.  
1.6.4 Apoptosis pathway  
  PARK2 controls the intrinsic mitochondrial threshold for cytochrome c release, 
thereby protecting cells from apoptotic stress [123, 124]. However, the presence 
of PARK2 in mitochondria is not sufficient to prevent cytochrome c release, 
suggesting that the anti-apoptotic function of PARK2 may be indirect, probably 







activity of several proteins belonging to the pro- and anti-apoptotic BCL-2 family, 
including BAX, MCL1 and BCL-2 [113, 125-127]. Of note, after apoptosis onset, 
PARK2 is cleaved by Caspase-1 and Caspase-8 [128, 129]. However, compared 
to the well-established protective function in neurons, the role of PARK2 in 
regulation of cancer cell apoptosis remains elusive. In cancer cells derived from 
the liver or breast, PARK2 expression augments the apoptotic cell death induced 
by HDAC inhibitors and microtubule-stabilizing drugs [65, 67]. Park2-/- 
hepatocytes are more resistant to anti-cancer drugs than the wild type counterpart 
[78]. Additionally, PARK2 sensitizes HeLa cells to TNF-α induced apoptosis 
[130]. Together, these observations suggest that PARK2 generally exerts an anti-
apoptosis function but it also sensitizes cancer cells to certain stimuli.  
1.6.5 Cancer cell metabolism 
  Warburg effect. Reprogramming energy metabolism is one of the hallmarks of 
cancer [131]. During malignant transformation, cancer cells often switch from 
mitochondrial respiration to aerobic glycolysis to sustain the bioenergetics and 
biosynthetic requirement (known as Warburg effect). PARK2 is a p53 target gene 
and negatively regulates glucose uptake, oxygen consumption, glycolysis and 
lactate production, mitigating the Warburg effect [29]. The mechanism underlying 
the inhibitory activity of PARK2 may be by regulating the mitochondrial function 
as well as the expression/activity of metabolic enzymes. Proteomic studies have 
identified many metabolic enzymes which might be regulated by PARK2 [113, 
122, 132-134], albeit the functional consequences of most alterations need to be 





PDHA1, which induces mitochondrial oxidative phosphorylation and inhibits 
glycolysis [29, 122].  
  Anti-oxidant defense. Park2 mutant flies or mice show defect in anti-oxidant 
defense [122, 135-137]. Consistently, ectopic PARK2 expression reduces the 
ROS level and increases the glutathione (GSH) level in cells [29, 138], while 
PARK2 mutants decrease the GSH and elevate the intracellular oxidative damage 
[139]. Thus, loss of PARK2 may contribute to ROS production during oncogenic 
transformation, similar to the effect of p53 inactivation. Paradoxically, PARK2 
activity may be required for KRAS-driven tumors to maintain mitochondrial 
quality control and buffer the excessive oxidative stress, since functional 
mitochondria and mitochondrial ROS generation are essential for the growth of 
those tumors [140, 141]. In such a context, PARK2 becomes a pro-survival 
protein in KRAS-transformed cancer cells. On the other hand, excessive ROS 
modulates the sulfonation, protein folding and solubility of PARK2, and thus 
represses its activity [142-145]. 
1.6.6 PARK2 in the receptor tyrosine kinase pathway 
  PARK2 interacts with Eps15 and EGFR upon EGF treatment [146]. Loss of 
PARK2 might accelerate EGFR endocytosis and degradation, and decrease the 
EGFR-AKT signaling. However, overexpression of PARK2 in glioma cells 
paradoxically inhibits signaling through AKT/mTOR [63]. Moreover, PARK2 is 
able to down-regulate VEGFR2 in gliomas [63], thus it may have a role in 





Figure 1.7 Mapping targets and/or pathways associated with PARK2 
deficiency to cancer hallmarks defined by Hanahan and Weinberg (2011) 
[131].  MSD, microtubule-stabilizing drug.   
1.7 Project aims 
  As described above, PARK2 (PARKIN) is an E3 ubiquitin ligase involved in 
multiple signaling pathways and cellular processes (Figure 1.7). Activity of 
PARK2 is tightly regulated through inter- and intra-molecular interactions, 
implying its critical function. Notably, frequent PARK2 inactivation has been 
identified in various human cancers. In a previous study from our lab, PARK2 
was found deleted and down-regulated in GBM [52]. However, its precise role in 
GBM still remains inconclusive and obscure [147]. Thus, this project was 
initiated with the specific aims as follows, 
1) To characterize genomic inactivation and expression of PARK2 in GBM; 
2) To examine the function of PARK2 in GBM; 
3) To decipher the molecular events and signaling pathways underlying the 
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2.1 Cell culture  
  HEK293T, HEK293, HCT116, HCT116TP53-/-, HeLa, immortalized murine 
embryonic fibroblast (MEF, kindly provided by Dr Yoshiaki Ito, Cancer Science 
Institute of Singapore), A172 (kindly provided by Dr Koichi Okumura, Cancer 
Science Institute of Singapore), U87-MG, U138-MG, U251-MG and U343-MG 
(hereafter referred to as U87, U138, U251 and U343, respectively), T98G, and 
CAOV3 were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% (vol/vol) fetal bovine serum (FBS) and 1% (vol/vol) 
penicillin/streptomycin, at 37℃, 5% CO2 in a humidified atmosphere. A2008, 
C13, CAOV2, OVCA433 were cultured in RPMI1640 supplemented with 10% 
(vol/vol) FBS and 1% (vol/vol) penicillin/streptomycin. COV504 and OVCAR5 
were cultured in RPMI1640 supplemented with 20 IU/L insulin, 10% (vol/vol) 
FBS and 1% (vol/vol) penicillin/streptomycin. EFO21 (kindly provided by Dr 
Ruby Huang, Cancer Science Institute of Singapore) were maintained in DMEM 
supplemented with 20% (vol/vol) FBS, 1mM sodium pyruvate, 1X non-essential 
amino acids and 1% (vol/vol) penicillin/streptomycin. OAW28 (kindly provided 
by Dr Ruby Huang, Cancer Science Institute of Singapore) were maintained in 
DMEM supplemented with 10% (vol/vol) FBS, 20 IU/L insulin, 1 mM sodium 
pyruvate and 1% (vol/vol) penicillin/streptomycin. OV7 and OV56 were 
maintained in DMEM/F12 supplemented with 10% (vol/vol) FBS, 20 IU/L 
insulin, hydrocortisone and 1% (vol/vol) penicillin/streptomycin. All GBM cell 
lines were authenticated by short tandem repeat analysis with Geneprint 10 






  Both FLAG-tagged and HA-tagged PARK2 vectors were constructed based on 
pcDNA3.1 plasmid and were further introduced into both pMSCV-PIG and 
pBABE-Puro vectors. Point mutations were introduced by site-directed 
mutagenesis. Lentiviral β-catenin overexpression constructs (including WT, Δ45 
and S33Y mutants) were generated based on the backbone of SHC003 (Sigma) 
using Nhe I and Fse I sites from parental plasmids (a gift from Dr Bert Vogelstein, 
Johns Hopkins University). EGFP-tagged EGFR vector was subcloned from 
pCMV6-EGFR-TurboGFP (kindly provided by Dr Boopathy Gandhi Theerthagiri 
Kuppusamy, Institute of Molecular and Cell Biology, Singapore) to pEGFP-C2 
vector. FLAG-tagged-Ubiquitin was cloned from a human UBB cDNA, and 
inserted into p3xFLAG-CMV vector using EcoR I and Xba I sites. Ubiquitin 
G76V mutant was constructed by site-directed mutagenesis. All the shRNA 
constructs were made with PLKO.1 backbone using Age I and EcoR I sites.  
2.3 Modulation of gene expression and generation of stable cell lines 
  Non-targeting control siRNA (siGENOME Non-Targeting siRNA Pool #2) and 
PARK2-targeting siRNAs were purchased from Thermo Scientific, and were 
transfected using RNAi MAX (Invitrogen). The sequences of all siRNAs and 
shRNAs are listed in Table 2.1. For lentiviral particle production, HEK293T cells 
were co-transfected using jetPRIME (Polyplus-transfection) with shRNA 
constructs, SHC003-based overexpression constructs and MISSION packaging 





pBABE-Puro-based vectors were co-transfected together with Env and Gagpol 
plasmids into HEK293T. The culture medium was replaced with fresh medium 
after 6 h, and supernatants were harvested through syringe filters (pore size 0.45 
μm) at 48 h and 72 h post transfection. For generation of stable lines, the cells 
were infected with indicated viral particles in the presence of 8 μg/mL polybrene 
followed by puromycin selection. Cells with stable expression of GFP or PARK2 
used in all the experiments (except for Figure 4.2) throughout the study were 
generated by pMSCV-PIG based vectors. In Figure 4.2, all stable cell lines were 
generated by pBabe-Puro-based vectors. 
Table 2.1 Sequences of shRNAs and siRNAs 


















2.4 Antibodies and chemicals 
  Antibodies specific for PARK2 (PRK8), non-phospho-β-catenin, β-catenin, 
Total-AKT, phospho-AKT (Ser473), phospho-AKT (Thr308), phospho-p70 S6K 
(Thr421/Ser424), p70 S6K, phospho-GSK-3β (Ser9), phospho-EGFR (Tyr1068), 
EGFR, TCF4, Cyclin D1, ATG5, Ubiquitin, HA, Histone H3 and GAPDH were 
purchased from Cell Signaling Technology. Antibodies specific for c-Myc (C-19), 
p27 (C-19), α-Tubulin (TU-02) and phospho-ERK1/2 (12D4) were from Santa 
Cruz. Antibodies specific for β-actin and FLAG M2 were from Sigma. Antibodies 
specific for PARK2 (ab55426), GSK-3β and GFP were from Abcam, BD 
Biosciences, and MBL, respectively. ICG001 was from Tocris, and also provided 
by Dr Michael Kahn (University of Southern California). MK2206 was from 
Selleckchem. Recombinant human EGF, cycloheximide, PKF-118-310, polybrene, 
and puromycin were from Sigma. MG132 was from Nacalai Tesque. 
Recombinant murine Wnt-3a was from Peprotech. 
2.5 Co-immunoprecipitation 
  Cells were treated either with or without 10 μM MG132 for indicated durations 
before lysis. Indicated antibody was added and incubated overnight with each cell 
lysate at 4℃. Protein A/G PLUS-Agarose beads (Santa Cruz) were added after 
washing for 3 times with lysis buffer. After 2-hour incubation, beads were washed 
four times, 5 minutes per wash in IP buffer (50 mM Tris, pH 7.6, 100 or 150 mM 
NaCl, 2 mM EDTA, 0.2% Nonidet P-40). Where applicable, anti-FLAG M2 





immunoprecipitation assay. Immunoprecipitated proteins were eluted by boiling 
with sample buffer for 5 minutes. 
2.6 Western blotting  
  Cells were lysed with M-PER® Mammalian Protein Extraction Reagent (Thermo 
Scientific) supplemented with 1X protease inhibitor cocktail (Roche), 0.2 mM 
sodium orthovanadate, and 1 mM phenylmethylsulfonyl fluoride. BCA assay 
(Santa Cruz) was used for protein quantification. Cell lysates or IP elutes were 
subjected to SDS-PAGE followed by either conventional wet transfer or dry 
transfer using iBlot® Gel Transfer Device (Invitrogen). Membranes were 
incubated with antibodies as indicated and exposed to secondary HRP-conjugated 
antibodies (Millipore). 
2.7 Quantitative real-time and cDNA microarray analysis 
  Total RNA was extracted using RNeasy Kit (Qiagen) and processed to cDNA 
with Superscript III (Invitrogen). Quantitative real-time PCR analysis was 
performed using Kapa SYBR Fast Master Mix (KAPA Biosystems) on a 7500 
Real-time PCR System (Applied Biosystems). The sequences of PCR primers are 
listed in Table 2.2. GeneChip® Human Genome U133 Plus 2.0 Array (Affymetrix) 







Table 2.2 Sequences of primers used for qRT-PCR 
Name Sequence (5’→3’) 
GAPDH forward GTCAGTGGTGGACCTGACCT 
GAPDH reverse AGGGGTCTACATGGCAACTG 
CCND1 forward GCCTCTAAGATGAAGGAGAC 
CCND1 reverse CCATTTGCAGCAGCTC 
TCF4 forward CTGCCTTAGGGACGGACAAAG 
TCF4 reverse TGCCAAAGAAGTTGGTCCATTTT 
LEF1 forward AATGAGAGCGAATGTCGTTGC 
LEF1 reverse GCTGTCTTTCTTTCCGTGCTA 
MYC forward CGTCTCCACACATCAGCACAA 
MYC  reverse TCTTGGCAGCAGGATAGTCCTT 
AXIN2 forward CAAGGGCCAGGTCACCAA 
AXIN2 reverse CCCCCAACCCATCTTCGT 
EGFR forward GGAAAAGAAAGTTTGCCAAG 




  Tissue microarray (TMA, purchased from Biomax, and also kindly provided by 
Dr YU Shizhu, Tianjin Medical University General Hospital) containing gliomas 
and corresponding normal tissues were prepared and incubated with anti-β-
catenin antibody (Cell Signaling Technology). The staining results were evaluated 
and quantified by two independent pathologists by the percentage of β-catenin-
positive cells: negative (score = 0), 1-25% (score = 1), 26–50% (score = 2), 51-75% 
(score = 3) and more than 76% (score = 4).  
2.9 Short-term cell proliferation assay 
  Cells were seeded into a 96-well plate at 3,000 cells/well and cultured for the 





indicated concentrations of drugs or solvent for 72 hours. A checkerboard method 
was employed to optimize the ratio of drug combination. Briefly, the dilutions of 
drugs (A) were made horizontally and the dilutions of drug (B) vertically in a 96-
well plate. Optimal concentration was chosen as the ratio between two drugs 
which could achieve highest anti-cancer efficacy. Cell viability was assessed 
using the MTT (3-(4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide) 
method. In brief, 10 μL of 12 mM MTT solution was added into each well 
followed by 3-hour incubation which was stopped by adding 100 μL of STOP 
solution (2% acetic acid, 16% SDS, 42% DMF). Samples were then mixed 
thoroughly and measured at 570 nm for absorbance. 
2.10 Long-term cell proliferation assays 
  The cells were seeded into 6-well plates at 5,000 cells/well and treated with 
indicated drugs for 10-12 days. At the endpoints of the assay, cells were fixed, 
stained with crystal violet and photographed.  
2.11 Soft agar colony formation assay  
  Basal layer was prepared by mixing equal volume of 1.25% (wt/vol) agarose 
(DNA grade) with 2X DMEM plus 20% (vol/vol) FBS. Top layer was prepared 
by mixing equal volume of 0.75% (wt/vol) low-melting agarose with 2X DMEM 
plus 20% (vol/vol) FBS. Basal layer mixture was added into each well in a 12-
well plate and allowed to solidify before seeding cells. Appropriate amount of 
cells were added into 0.5 ml of pre-warmed top layer mixture and overlaid onto 





weeks, colonies were stained using 0.2% (wt/vol) crystal violet in 4% (wt/vol) 
paraformaldehyde, and then photographed by a dissecting microscope.   
2.12 Tumor formation assay in nude mice 
  Three million of U251-control or U251-PARK2 cells were mixed with 80 μL of 
Matrigel solution (BD Biosciences) per injection, and the mixture was injected 
subcutaneously on the upper flanks of nude mice. Tumor volume was measured 
every week for 8 weeks. Mice experiments were approved by the Institutional 
Animal Care and Use Committee both in NUS and Cedars-Sinai Medical Center, 
UCLA. 
2.13 Bioinformatics and data analysis 
  Copy number data of human cancer cell lines were extracted from the Cancer 
Cell Line Encyclopedia database. Copy number data of lower grade glioma as 
well as glioblastoma were collected from The Cancer Genome Atlas via cBio 
Cancer Genomics Portal and analyzed with IGV software. High-amplitude 
deletion (gene dosage value < -1) in cell lines was defined based on the 
assumptions that loss of both alleles occurred in more than 75% of total cells. 
High-amplitude deletion (gene dosage value < -0.5) in glioma samples was 
defined with following assumptions: (i) loss of both alleles was present in more 
than 80% cancer cells, and (ii) normal tissue contamination was less than 20% 
[148]. GBM mRNA-expression and survival data were obtained from TCGA via 
cBio Cancer Genomics Portal, Rembrandt database and GSE4271 [25, 149]. 





TCGA cohort. Somatic PARK2 mutations in cancer were summarized from 
COSMIC, TCGA as well as other publications [48, 49, 53, 60, 147, 150, 151]. 
Parkinson's disease-associated PARK2 mutations were analyzed from LOVD 
Database. All data were subtracted and analyzed by 1st Feb, 2014. 
  To calculate the conservation score of PARK2 protein, protein sequences of 
PARK2 from various species were collected from NCBI in FASTA file, and 
aligned by ClustalX 2.1. In detail, PARK2 orthologues from following species 
were used for alignment, Danio rerio, Gallus gallus, Rattus norvegicus, Mus 
musculus, Sus scrofa, Bos taurus, Felis catusi, Equus caballus, Nomascus 
leucogenys (isoform 1), Saimiri boliviensis boliviensisi, Callithrix jacchus, Pan 
troglodytes (isoform 5) and Homo sapiens (isoform 1). Conservation score 
(ranging from 0 to 100) was plotted for each column (amino acid residue) of the 
alignment on the basis of alignment quality. A high score indicates a well-
conserved residue in that particular column; a low score indicates low 
conservation.  
  In statistical analysis, the log-rank test was used to compare the survival 
difference. Unless otherwise stated, Student’s t-test (two-tailed) was applied for 
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  PARK2 (PARKIN) encodes a well-conserved RBR type E3 ubiquitin ligase. 
Many studies have revealed a complex regulation of PARK2 activity through 
multiple intra- and inter-molecular interactions [9-12], implying its critical 
function in human. Indeed, germline mutations of PARK2 have been identified as 
a cause of dopaminergic neuron loss in recessive familial early onset 
Parkinsonism [14]. Many Parkinson's disease-associated PARK2 mutations have 
been recorded in LOVD Database (Appendix 2). 
  Somatic alterations of PARK2 have been reported among various human 
malignancies [147]. However, the mechanism of PARK2 inactivation seems to 
vary among different cancer types. Single nucleotide polymorphism array (SNP 
array) and microarray-based comparative genomic hybridization (array-CGH) 
techniques help to detect chromosomal deletions and duplications in human 
cancers. By using SNP arrays, our lab previously reported the loss of PARK2 in 
glioblastoma [52]. Similar observations were also shown by other independent 
studies [2, 23, 53]. With recent advances in next-generation sequencing (NGS) 
technology, large bodies of information have been generated in the process of 
decoding cancer genomes, providing us with an opportunity to evaluate the 
somatic mutation pattern of PARK2.  
  In this chapter, cross-cancer analysis of copy number alteration and somatic 
mutation of PARK2 will be presented. The altered expression of PARK2 and its 






3.2.1 Pan-cancer analysis of somatic PARK2 mutations 
  To determine comprehensively the somatic mutations affecting PARK2, a large 
number of datasets were interrogated (see Section 2.13). One hundred and sixteen 
PARK2 mutation events were recorded across different tumor types (Appendix 3). 
Fifteen percent of those mutations lead to detrimental frameshifts, missplicings or 
pre-mature truncations of the PARK2 protein. Notably, several sites were mutated 
recurrently in multiple cancers (Figure 3.1A), including A46, T173, T240, R275, 
P294, P343, etc. As PARK2 is an evolutionally conserved protein, the 
conservation score of each amino acid residue across PARK2 protein was 
calculated (see Section 2.13). Of note, most cancer-associated recurrent mutations 
of PARK2 occurred in the evolutionally conserved amino acid residues (Figure 
3.1A), suggesting their biologic relevance. Interestingly, over 20% of cancer-
associated somatic mutations of PARK2 occurred in the sites where germline 
mutations have been reported in Parkinson’s disease (Figure 3.1B).  
3.2.2 High-amplitude PARK2 deletion is prevalent in human cancer cell lines 
and cancer specimens 
  As a result of genomic instability, DNA copy number variations (CNVs) are an 
important feature of genetic alterations in cancer. Our lab has developed an 
algorithm to estimate the CNV in cancer specimens [148]. By employing this 
method with slight modification (see Section 2.13), I re-analyzed the CNV data of 





specimens. Copy number loss of PARK2 was observed in 10.3% (100/971) of 
human cancer cell lines (Figure 3.2A). High-amplitude PARK2 deletions were 
frequently observed in primary tumor samples of various tissue origins. Among 
all samples analyzed, ovarian serous cystadenocarcinoma (34.6%, Figure 3.2B), 
GBM (19.3%, Figure 3.2D), liver cancer (14.0%) and breast invasive carcinoma 
(9.8%) showed high frequency of PARK2 loss. Interestingly, the frequency of 
PARK2 deletion increased from lower grade glioma (4.83%) to GBM (19.3%) 
(Figures 3.2C-D), indicating that loss of PARK2 may contribute to the progression 
of glioma.  
 
Figure 3.1 Pan-cancer analysis of somatic PARK2 mutations. A, Recurrent 
mutations are highlighted in upper diagram. Frequency of somatic mutations 
(black) and conservation score of each amino acid (green) are indicated in lower 
diagram. B, Cancer-derived PARK2 mutations which have been reported in PD 
are highlighted in upper diagram. Frequency of all PD-derived mutations (red) 






Figure 3.2 High-amplitude PARK2 deletions in human cancer cell lines and 
tumor samples. High-amplitude deletion of PARK2 (see Section 2.13) occurred 
in (A) 100 out of 971 cancer cell lines (CCLE), (B) 194 out of 561 ovarian serous 
cystadenocarcinoma samples (TCGA), (C) 13 out of 269 lower grade glioma 
samples, and (D) 96 out of 497 glioblastoma (GBM) samples (TCGA). Only cases 







3.2.3 PARK2 expression is down-regulated in various cancer types 
  To examine PARK2 expression, cDNA microarray data from TCGA and several 
public datasets were extracted. The transcriptional level of PARK2 was 
significantly lower in ccRCC, breast invasive carcinoma, colon adenocarcinoma 
and GBM, when comparing with their non-tumor counterparts (Figures 3.3A-D). 
The down-regulation of PARK2 transcripts in glioma compared to epilepsy 
tissues was further verified in an independent cohort (Figure 3.3E).  
 
Figure 3.3 Down-regulation of PARK2 transcription in human cancer 
samples. cDNA microarray data were analyzed from (A-D) TCGA database  and 
(E) GSE4290. Lower grade glioma group includes grade 2 and grade 3 samples. 





  The expression level of PARK2 protein was further screened in a panel of cancer 
cell lines. PARK2 protein appeared low and absent in over 70% of cancer cell 
lines that I examined (Figures 3.4A-C). Only 2 out of 11 ovarian cancer cell lines 
showed detectable PARK2 protein (Figure 3.4C). Three out of 6 established GBM 
cell lines showed very low or undetectable PARK2 (Figure 3.4B). Notably, 
PARK2 protein was down-regulated in HCT116TP53-/- isogenic cells (Figure 3.4B), 
compared to their wild type counterparts, suggesting that PARK2 expression is 
maintained by p53.   
 
Figure 3.4 Screen of PARK2 protein expression in cell lines. A, Detection of 
endogenous PARK2 protein in HEK293 cells. Pooled siRNAs targeting PARK2 
were applied to deplete endogenous PARK2. B, PARK2 protein expression in 
isogenic HCT116 cells, GBM cell lines, HeLa and MEF cells. C. PARK2 protein 





3.2.4 PARK2 expression predicts the prognosis of glioma patients 
  Next, the prognostic value of PARK2 expression in human cancers was analyzed. 
Notably, low mRNA expression of PARK2 predicted poor survival in all gliomas 
based on NCI Rembrandt database (Figure 3.5A). Moreover, in different datasets 
lower PARK2 expression was strongly associated with worse prognosis in 
patients with lower grade glioma (Figure 3.5B), high grade glioma (Figure 3.5D), 
as well as GBM (Figure 3.5C). However, no significant association between 
PARK2 expression level and survival was observed in patients with ovarian 
serous cystadenocarcinoma (Figure 3.5E). Collectively, these findings strongly 







Figure 3.5 Identification of PARK2 as a prognostic marker for glioma. A, 
Low PARK2 expression (fold change < -2, n=84) was associated with poor 
survival of glioma patients based on Rembrandt dataset (all glioma, n=344). High 
PARK2 group consists of the rest 260 patients. B-C, Low PARK2 expression 
(mRNA expression Z-Score < Mean + 0.05SD, n=241, in lower grade glioma; 
mRNA/miRNA expression Z-score < Mean + 0.4SD, n=265, in GBM) was 
associated with poor survival based on TCGA dataset. High PARK2 expression 
group consisted of 130 patients with lower grade glioma and 142 patients with 
primary GBM, respectively. D, Low PARK2 expression (Low PARK2 expression, 
n=41; High PARK2 expression, n=36) predicted poor survival of patients with 
high grade glioma. Data were analyzed based on GSE4271 [25, 149]. E, PARK2 
expression (mRNA expression Z-Score < Mean - 0.5SD, n=145) was not 
associated with survival of ovarian serious cystadenocarcinoma patients (TCGA). 







  Genome instability is one of the hallmarks of cancer, and somatic mutation and 
copy number loss are commonly observed in genes encoding tumor suppressors. 
Based on pan-cancer genomic analysis of PARK2 mutations, at least 15% of those 
mutations are deleterious to the protein function. In addition, several recurrent 
mutations were identified across different functionally important domains, albeit 
the impact of most mutations on PARK2 activity needs further characterization. 
Selvaraju Veeriah et al. showed that cancer-derived R42C, N254S, R275Q, and 
E344G mutants lost their ability to suppress tumor cell growth [53], suggesting 
that somatic mutations compromise the function of PARK2 during tumorigenesis. 
Given the fact that some cancer-associated PARK2 mutations are also present in 
Parkinson’s disease, it is interesting to evaluate the cancer risk of patients with 
familiar Parkinson’s disease. Indeed, JH Olsen et al. showed that men and women 
with Parkinson’s disease in Denmark had increased risk for breast cancer, 
malignant melanoma, non-melanocytic skin cancer and brain cancer [152]. Recent 
study conducted in East Asian populations also indicated that Parkinson’s disease 
patients had higher risk for multiple types of cancer, including brain and kidney 
cancers, and melanoma [153]. However, another report based on an independent 
cohort of Parkinson’s disease patients did not reach the same conclusion [154]. 
Thus, the association between PARK2 genotype and cancer susceptibility needs to 
be further studied. Large scale and multi-ethnic epidemiological study of patients 





information for the association between PARK2 inactivation and cancer 
predisposition in human. 
  PARK2 has been shown to be ubiquitously expressed in normal tissues [27]. The 
loss of PARK2 expression in human cancer cell lines is frequently observed. 
More than 10% of human cancer cell lines showed copy number loss of PARK2. 
And over 70% of the cell lines that I examined showed low or undetectable 
expression of PARK protein, suggesting that PARK2 inactivation may be a 
beneficial event for cancer cells. Moreover, p53 was identified as a positive 
regulator of PARK2 expression. However, across the cancer cell lines that I 
examined, wild type TP53 status did not significantly correlated with PARK2 
expression, suggesting that high frequency of PARK2 loss may be triggered by 
multiple mechanisms.   
  Copy number analysis of 269 low grade glioma samples and 497 GBM samples 
showed frequent high-amplitude PARK2 deletion. Previous study from our lab 
showed the reduction of PARK2 mRNA in glioma samples comparing to normal 
brain [52]. In this study, our bioinformatical analysis further suggests the down-
regulation of PARK2 transcriptional level in tumor samples from multiple cohorts 
of glioma patients. For the first time, we report the prognostic value of PARK2 
expression in both low grade and high grade gliomas (including GBM). High 
PARK2 expression can serve as a strong positive prognostic marker for patients 
with glioma, especially low grade glioma. In an attempt to examine the protein 
expression of PARK2 in primary glioma tissues, two different PARK2 antibodies 





but unfortunately, no specific signals were observed by IHC staining (data not 
shown). Alternatively, our immunoblotting analysis showed weak or absent level 
of endogenous PARK2 protein in GBM cell lines, comparing to HEK293 cells. In 
line with our data, recent study reported that PARK2 protein was present in 
normal brain tissues but down-regulated in glioma samples [69].  
  Interestingly, an internal in-frame Kozak sequence is found in the full-length 
PARK2 open reading frame (ORF), which initiates an alternative translation and 
produces a special form of PARK2, ΔUBL, lacking the N-terminal ubiquitin-like 
(UBL) domain [38]. The PARK2 antibody (4211S from Cell Signaling 
Technology) used in this study can specifically recognize two bands of human 
PARK2 proteins (long form and short form, respectively), and one band of murine 
Park2. Long form PARK2 represents the full-length PARK2, while the short form 
PARK2 appears with a molecular weight of 43 kD which fits ΔUBL. The 
expression of short form PARK2 appeared to be associated with long form, since 
cells with short form expression always concurrently express the long form. The 
functional interplay between long form and short form awaits further study. 
  Collectively, these findings suggest that PARK2 is targeted by various genomic 
defects in human cancers, especially glioma. PARK2 loss might contribute to the 






Chapter 4              
PARK2 attenuates glioblastoma cell proliferation both in 








  Somatic alterations of PARK2 are also prevalent among various human 
malignancies. The wide inactivation of PARK2 in human cancers has been 
summarized in Chapter 1.  Park2-deficient mice are more susceptible to colorectal 
adenoma, hepatocellular carcinoma and γ-irradiation-induced tumorigenesis. 
Several studies have reported that restoration of PARK2 expression suppresses 
the proliferation of PARK2-deficient cancer cells derived from brain, breast, 
colon, lung and pancreas [53, 54, 56, 60, 62, 63]. My initial analysis of PARK2 
mutation, copy number loss, and under-expression suggested that PARK2 is a 
potential tumor suppressor in human cancers, especially in glioma. More 
functional studies are required to explore the role of PARK2 in human cancers. 
  To investigate dysregulation of PARK2 in glioma, overexpression and loss-of-
function approaches were applied in this study. The activity of three recurrent 
cancer-associated PARK2 mutations, namely T173A, T240M and P294S, were 
also examined. Expression of ectopic PARK2 suppressed glioma cell proliferation 
both in liquid culture and in immunocompromised mice, while depletion of 
endogenous PARK2 in glioma cells promoted cell growth. Furthermore, cDNA 
microarray analysis was performed to compare the genes differentially expressed 
upon PARK2 overexpression. 
4.2 Results 





  To explore the role of PARK2 in GBM, cell line models with ectopic PARK2 
were established and investigated. GBM cells were infected with retroviral 
particles harboring GFP or PARK2 CDS (Coding DNA Sequence), followed by 
puromycin selection. MTT assay results showed that exogenous PARK2 
expression significantly reduced cell proliferation of GBM cells with undetectable 
or low PARK2 protein (Figures 4.1A-B). A172 cells with high PARK2 
expression were insensitive to PARK2 overexpression (Figure 4.1B). To access 
the effect of PARK2 overexpression on anchorage-independent growth of GBM 
cells, colony formation assays in soft agar were performed. Overexpression of 
PARK2 in GBM cells profoundly reduced their ability to form colonies in soft 
agar (Figure 4.1C). To evaluate the activity of cancer-associated PARK2 
mutations, three recurrent mutants, namely T173A, T240M, and P294S, were 
constructed based on retroviral vector and examined. All three mutants showed 
compromised growth suppressive activity in GBM cells, as U87 cells stably 
expressing PARK2 mutants formed more colonies than those cells expressing 







Figure 4.1 PARK2 overexpression suppresses glioblastoma cell growth in 
vitro. A, Western blot result showing the expression of ectopic PARK2 in GBM 
cells. B, MTT proliferation assay of GBM cell lines stably expressing either 
ectopic wild type PARK2 or GFP (Control) under either 10% FBS or 1% FBS 
conditions. C, Soft agar colony formation assay of GBM cell lines with either 
ectopic wild type PARK2 or Control (GFP) protein expression. Data represent 






Figure 4.2 Cancer-derived PARK2 mutants show compromised growth-
suppressive ability. A, U87 cells stably expressing either wild type PARK2 or its 
cancer-derived mutants (T173A, T240M and P294S) were subjected to soft agar 
colony formation assay. B, Western blot result showing the expression levels of 
wild type and mutant PARK2 in U87 cells. Data represent Mean ± SD. n.s., not 
significant; **, P < 0.01. 
 
  Furthermore, endogenous PARK2 was silenced in GBM cells by both siRNA- 
and shRNA-mediated approaches. Depletion of endogenous PARK2 in U138 cells 
by pooled siRNAs significantly enhanced cell proliferation and colony formation 
in soft agar (Figures 4.3A-C). Moreover, U138 and U343 cells stably expressing 
shRNA targeting PARK2 showed marked increased growth of colonies in soft 
agar (Figures 4.4A-B). To confirm the specificity of the shRNA knockdown assay, 
rescue experiments were performed by taking advantage of the fact that the sh-
PARK2-1 targeted the 3’-UTR of PARK2 transcripts and PARK2 over-
expression vector contained only CDS. Importantly, reintroduction of ectopic 








Figure 4.3 siRNA-mediated depletion of endogenous PARK2 promotes U138 
cells growth in vitro. U138 cells were transfected with either non-targeting 
Control siRNA or pooled siRNAs targeting PARK2. A, Western blot result 
showing the expression levels of PARK2 after 72 hours post siRNA transfection.  
Twenty-four hours post-transfection, cells were then seeded for (B) MTT assay or 
(C) soft agar colony formation assay. Data represent Mean ± SD. **, P < 0.01. 
 
 
Figure 4.4 shRNA-mediated depletion of endogenous PARK2 enhances the 
colony-forming ability of GBM cells in soft agar. A-B, U138 and U343 cells 
were transduced with lentiviral particles harboring either non-targeting shRNA 
(sh-Control) or shRNA targeting PARK2 (sh-PARK2-1) and subjected to western 
blot analysis (A) and soft agar colony formation assay (B). C-D, U343 cells stably 
expressing sh-PARK2-1 or sh-Control were transduced with retroviral particles 
encoding exogenous PARK2. Subsequently, cells were subjected to western blot 
analysis (C) and soft agar colony formation assay (D). Data represent Mean ± SD. 






4.2.2 PARK2 suppresses glioblastoma cell growth in vivo 
  To assess whether PARK2 affects the tumorigenicity of GBM cells in vivo, 
U251 cells stably expressing PARK2 or GFP (Control) were subcutaneously 
injected into nude mice and tumor volumes were measured every week for 8 
weeks. PARK2 overexpression substantially delayed tumor progression and 
reduced the tumor burden (Figures 4.5 A-B).  
 
Figure 4.5 PARK2 suppresses glioblastoma cell growth in vivo. A, U251 cells 
stably expressing either Control (GFP) or PARK2 were injected subcutaneously 
on the upper flanks of nude mice. Tumor volumes were measured every week. B, 
Image shows the resected tumors from nude mice. Data represent Mean ± SD. **, 





4.2.3 PARK2 affects multiple signaling pathways in U251 cells 
  To characterize further the molecular mechanisms underlying the glioma-
suppressive function of PARK2, cDNA microarray analysis of U251-PARK2 and 
U251-Control cells was performed. Pathway enrichment analysis revealed that 
many pathways involving metabolism, focal adhesion, actin cytoskeleton, 
ErbB/EGFR signaling, TGF-β signaling, and Wnt signaling were overrepresented 
in both KEGG Pathway and WikiPathways platforms (Figures 4.6 A-B), 
suggesting the potential involvement of PARK2 in those pathways.  
  As PARK2 is an E3 ubiquitin ligase, it is very likely that PARK2 modulates the 
activity of key proteins in those pathways. To explore this, serial experiments 
were conducted to examine the potential partners or substrates of PARK2. Co-
immunoprecipitation (co-IP) assay showed that PARK2 could interact with 
several important proteins, including LIMK1, β-catenin and EGFR. The detailed 
effects of PARK2 on regulating β-catenin and EGFR proteins as well as 
downstream signaling were explored further in this study; and the results are 






Figure 4.6 Pathways regulated by PARK2 in GBM cells. Pathway enrichment 
analysis of cDNA microarray data derived from U251 cells stably expressing 
either ectopic Control or PARK2 protein. Genes with probes showing fold change 
greater than 2 were used in this analysis. Data represent top overlapped pathways 
identified to be enriched in both KEGG Pathway (A) and WikiPathways (B). All 
pathways indicated had adjusted P values less than 0.05. 
 
Figure 4.7 PARK2 inhibits GBM cell migration. Wound healing assay of U251 






  In this chapter, our over-expression and loss-of-function studies of PARK2 in 
GBM cells strongly suggest that PARK2 is a suppressor of GBM proliferation 
both in vitro and in vivo.  
  We showed that three cancer-derived PARK2 mutants (T173A, T240M and 
P294S) were loss-of-function. Selvaraju Veeriah et al. also showed that R42C, 
N254S, R275Q, and E344G mutants lost their ability to suppress tumor cell 
growth [53]. Given that PARK2 protein is tightly regulated by intra-and inter- 
molecular interactions, and its activity is highly sensitive to conformational 
change, most PARK2 mutations in conserved amino acid residues are likely to 
compromise the tumor-suppressive function of PARK2.  
  Tumor formation assay of U251 cells also confirmed the glioma-suppressive role 
of PARK2, similar to the result reported by Yeo et al. using the intracranial tumor 
model of U87 cells [63]. To date, no evidence of increased glioma incidence in 
Park2 knockout mice without additional genetic lesions has been reported, 
suggesting that Park2 inactivation alone is not sufficient to drive glioma 
tumorigenesis. Murine models with oncogenic background might be required for 
Park2 study in glioma. A similar example was presented in a colon adenoma 
model [60]. Park2+/-; Apc+/min mice show a 4-fold increase in the incidence of 
adenomas, and earlier onset of intestinal neoplasia compared with Park2+/+; 





adenoma, suggesting that Park2 deficiency can cooperate with other oncogenic 
event to promote neoplastic transformation.  
  To gain information of potential downstream signaling pathways affected by 
PARK2, transcriptome analysis was applied. Notably, pathways including 
metabolism, focal adhesion, actin cytoskeleton, ErbB/EGFR signaling, TGF-β 
signaling, and Wnt signaling were significantly altered by PARK2 overexpression 
(Figure 4.6). In this study, the effects of PARK2 on regulating Wnt-β-catenin and 
EGFR signaling pathways were explored in depth (Chapters 5 and 6). Worthy of 
mention, LGR5, a stem cell marker, was among the top genes that are down-
regulated by PARK2 overexpression in U251 cells. In our cDNA microarray data, 
we also observed a significant induction of PTPRD transcripts upon PARK2 
overexpression. Since PTPRD is a putative tumor suppressor and severely 
silenced in glioma [155-157], to study how PARK2 can turn on another tumor 
suppressor in GBM would be of interest.   
  Interestingly, LIMK1, an important protein regulating cell migration, invasion 
and cytoskeleton [158-163], was identified as an interacting partner of PARK2 in 
our mass spectrometry analysis (data not shown). The interaction between 
PARK2 and LIMK1 was also reported by another study [164]. In vitro scratch 
assay showed that PARK2 overexpression in U251 cells could inhibit the cell 
migration (Figure 4.7). The anti-migration effect of PARK2 was also observed in 
other cancer types, including breast cancer [62] and ovarian cancer (data not 
shown). Thus, the PARK2-LIMK1 regulatory axis may exert functional impact on 





  All together, these results suggest that PARK2 is a multifaceted tumor 






Chapter 5                  








  As discussed in the Introduction, although PARK2 has been implicated in 
several cellular processes including microtubule organization, cell cycle 
progression, cancer metabolism and mitochondria homeostasis, its precise role in 
cancers, especially in GBM, still remains inconclusive and obscure. Thus, the 
molecular events and signaling underlying the functional relevance of PARK2 in 
GBM await further characterization. 
  Wnt signaling appears to be important for maintenance and chemo-/radio-
resistance of glioma cancer initiating cells [4-6]. cDNA microarray analysis of 
U251 cells with PARK2 overexpression revealed the strong enrichment of 
signaling of both Wnt and ErbB/EGFR among all the pathways that were 
significantly altered. In this chapter, I describe how PARK2 can reduce the 
activity of the canonical Wnt-β-catenin pathway, and decrease the intracellular 
level of β-catenin through ubiquitin-proteasome pathway. PARK2 physically 
interacted with β-catenin and promoted its ubiquitination in an E3 ligase activity-
dependent manner.  
5.2 Results 
5.2.1 PARK2 negatively regulates canonical Wnt-β-catenin pathway 
  The protein levels of canonical Wnt targets including Cyclin D1, c-Myc and 
TCF4, were markedly down-regulated upon PARK2 overexpression (Figures 
5.1A-B). In parallel, mRNA levels of CCND1, TCF4, MYC and LEF1 were 





stem cell marker and Wnt target gene [165, 166], was found down-regulated in 
both cDNA microarray and qRT-PCR assays (Figure 5.1D).   
 
Figure 5.1 PARK2 overexpression in GBM cells inhibits canonical Wnt-β-
catenin pathway. (A-B) Western blot analysis of gene expressions regulated by 
canonical Wnt signaling in GBM cells stably expressing either GFP Control (GFP) 
or PARK2. (C-D) qRT-PCR analysis of Wnt target genes in U251 cells stably 
expressing either GFP (Control) or PARK2. C and P represent GFP control cells 
and PARK2 overexpressing cells, respectively. Data of (C-D) represent Mean ± 
SD. **, P < 0.01. 
 
  Notably, β-catenin protein level itself was decreased after restoration of PARK2 
(Figure 5.1A). Knock-down of endogenous PARK2 with either pooled siRNAs or 
two individual siRNAs increased β-catenin protein level (Figures 5.2A-B). As 
nuclear β-catenin acts as a transcription activator for Wnt target genes, I next 
asked whether PARK2 affected the intracellular distribution of β-catenin. Cell 
fractionation assays showed that the nuclear proportion of β-catenin was 





  To test directly the effect of PARK2 on Wnt response, U251 cells either with or 
without PARK2 overexpression were stimulated with Wnt3a-conditioned medium, 
and the mRNA level of the most faithful Wnt target gene AXIN2 was measured. 
As expected, dramatic induction of AXIN2 was detected in U251-Control cells, 
whereas the response was attenuated by expressing PARK2 (Figure 5.4), 
suggesting that PARK2 restrains the activity of the canonical Wnt-β-catenin 
pathway. 
 
Figure 5.2 Depletion of endogenous PARK2 elevates β-catenin expression. 
Seventy-two hours after transfection, Western blot analysis was performed to 
examine β-catenin and PARK2 expression in response to PARK2 silencing by 
either (A) pooled siRNAs or (B) two individual siRNAs. 
 
Figure 5.3 PARK2 overexpression decreases the level of nuclear β-catenin. 
Cytosolic (Cyto) and nuclear (N) fractions of U138 and U343 cells stably 





analysis, and probed with β-catenin antibody. α-Tubulin and Histone H3 were 
used as loading controls for cytosolic and nuclear proteins, respectively. 
 
Figure 5.4 PARK2 overexpression in U251 cells reduces AXIN2 level in 
response to Wnt3a stimulation. U251 cells stably expressing either GFP 
(Control) or PARK2 were treated with complete growth medium (Normal), L-cell 
control medium (Control) or Wnt3a-conditioned medium (Wnt3a-CM) for 4 
hours. Subsequently, cells were harvested for qRT-PCR analysis of AXIN2 
expression. Data represent Mean ± SD. n.s., not significant; **, P < 0.01. 
 
 
Figure 5.5 PARK2 overexpression shortens the half-life of β-catenin. 
Cycloheximide chase assay was conducted to measure the β-catenin half-life in 
U251-C (expressing Control) and U251-P (expressing ectopic PARK2) cells. 
Cyclin D1 was used as a positive control. Cells were treated with 100 μg/mL 
cycloheximide for indicated durations before cell lysis. Relative amounts of β-
catenin were measured by ImageJ and normalized to their loading controls. 






5.2.2 PARK2 promotes β-catenin turnover through the proteasome pathway 
  As β-catenin is the key mediator of Wnt signaling, the mechanism regarding 
how PARK2 regulates β-catenin was further investigated. First, the half-life of β-
catenin in U251 cells decreased from over 8 hours to 6 hours upon expression of 
PARK2 as indicated by cycloheximide chase assays (Figure 5.5). Next, the major 
protein degradation machineries controlling β-catenin turnover, namely, 
autophagy-lysosome pathway and ubiquitin-proteasome pathway [167, 168], were 
examined. Depletion of ATG5, the essential component of autophagy, could not 
restore the β-catenin protein level (Figure 5.6A). However, proteasome blockade 
by MG132 abolished β-catenin down-regulation (Figure 5.6B). These results 
suggest that PARK2 down-regulates β-catenin through the proteasome pathway. 
5.2.3 PARK2 physically interacts with β-catenin 
  As PARK2 has E3 ligase activity, I hypothesized that PARK2 might directly 
bind and promote β-catenin degradation through the proteasome pathway. To test 
this, a series of endogenous and semi-endogenous co-immunoprecipitation (co-IP) 
assays were performed. In HEK293T cells stably expressing HA-tagged PARK2 
(HEK293T-P cells), PARK2 and β-catenin could be reciprocally pulled down by 
either β-catenin antibody or HA antibody (Figure 5.7A).  In U343 glioblastoma 
cells with PARK2-HA overexpression, PARK2 antibody pulled down 
endogenous β-catenin, and this interaction was further enhanced in the presence 
of MG132 (Figure 5.7B). Similar results were observed in U251-P and 





confirmed the interaction between PARK2 and β-catenin in two GBM cell lines 
(U343 and A172) and a colon cancer cell line HCT116 (Figure 5.8), suggesting 
that PARK2 physically bound to β-catenin irrespective of tissue origins.  
 
Figure 5.6 PARK2 promotes β-catenin turnover through the proteasome 
pathway. A, U251 cells stably expressing either Control or PARK2 proteins were 
transduced with lentiviral particles encoding either non-targeting control shRNA 
or shRNA against ATG5. Protein lysates were subjected to western blot analysis 
using indicated antibodies. B, Western blot analysis of β-catenin levels in GBM 
cells stably expressing either GFP control or PARK2 in the presence of either 
DMSO or MG132 (10 μM, 24 hours). Relative amounts of β-catenin were 
measured by ImageJ and adjusted to their loading controls. Values represent the 
relative expression of β-catenin after normalizing with its level in control cells 






Figure 5.7 Ectopic PARK2 interacts with β-catenin. A, In HEK293T cells 
stably expressing HA-tagged PARK2, co-IP assay were performed using either β-
catenin (left panel) or HA (right panel) antibodies. Equal amount of input cell 
lysate was used for each co-IP assay. B-D, Exogenously expressed PARK2 
interacted with endogenous β-catenin in (B) U343, (C) U251, and (D) HEK293T 
cells. Where applicable, cells were treated with 10 μM MG132. Arrow indicates 
the extra band of β-catenin (lane 4) which was pulled down by PARK2 antibody 
in the presence of MG132. B-C, Equal amount of input cell lysate was used for 
IgG and PARK2 IP assay. 
 
 
Figure 5.8 Endogenous interaction between PARK2 and β-catenin in human 
cancer cell lines. Co-IP of endogenous PARK2 with β-catenin in GBM cells and 
HCT116 cells are shown. N.D. means Not Detected. * indicates a non-specific 





  To extend these findings, co-IP was performed using immortalized MEF cells 
and showed that endogenous murine Park2 pulled down β-catenin (Figure 5.9), 
suggesting that the interaction is conserved from mice to humans. Surprisingly, 
this binding was independent of the phosphorylation status of canonical β-catenin 
degron, as Park2 interacted with both total and non-phospho-β-catenin (Figure 
5.9). Moreover, both β-catenin S33Y and β-catenin Δ45Y mutants, which are 
known to be phosphorylation-deficient in the canonical degron, were co-
immunoprecipitated with PARK2 antibody (Figure 5.10). Interestingly, 
appreciatable amount of low-mobility wild type or mutant β-catenin were 
repeatedly detected by both total and/or non-phospho- β-catenin antibodies 
(Figure 5.7, Figure 5.9 & Figure 5.10). These observations prompted me to 
examine whether PARK2 preferentially interacts with a special form of β-catenin, 
since β-catenin is a well-known phospho-protein with multiple phosphorylation 
sites. However, protein phosphatase treatment could not diminish the low-
mobility form of β-catenin which was co-immunoprecipitated with PARK2 
antibody (Figure 5.11), indicating that the decreased mobility of β-catenin is not 






Figure 5.9 Endogenous interaction between Park2 and β-catenin in MEF 
cells. PARK2 antibodies were used to enrich endogenous Park2 and its interacting 
partners in MEF cells. IP elutes were subjected to SDS-PAGE and probed with 
indicated antibodies. * indicates a non-specific band.  
 
Figure 5.10 PARK2 interacts with both wild type and phosphorylation-
deficient β-catenin. PARK2-HA was co-transfected with either wild type or 
phosphorylation-deficient β-catenin mutants into HEK293T cells for 24 hours. 
MG132 was added 4 hours before IP. Arrows indicate the extra band of β-catenin 







Figure 5.11 Lambda phosphatase treatment of proteins immunoprecipitated 
by PARK2 antibody. PARK2 complexes were enriched by PARK2 antibody in 
HEK293T cells transfected with PARK2-HA vector, and subjected to indicated 
treatments. Sodium orthovanadate and PhosSTOP phosphatase inhibitor cocktail 
were used to inactivate lambda phosphatase. * indicates a non-specific band. 
Arrow indicates the extra band of β-catenin before (lane 2) and after (lane 3) 
lambda phosphatase treatment.  
 
  Adenomatous Polyposis Coli (APC) is a crucial scaffold protein mediating β-
catenin degradation through the destruction complex. APC is frequently mutated 
in colon cancers, leading to hyper-activation of Wnt-β-catenin signaling [169, 
170]. To test whether APC is involved in PARK2-β-catenin interaction, 
Apcf/f MEF cells were transduced with viral particles expressing either GFP or 
GFP-IRES-Cre, and subjected to immunoprecipitation assay. After Cre 
recombinase-mediated excision of Apc, the levels of non-phospho-β-catenin and 
Cyclin D1 were markedly elevated in MEF cells (Figure 5.12A). Notably, 
endogenous β-catenin could no longer be co-immunoprecipitated with Park2 













Figure 5.12 Apc is required for Park2-β-catenin interaction. Apcf/f MEF cells 
were transduced with retroviral particles expressing either GFP or GFP-IRES-Cre, 
and subjected to (A) Western blot analysis and (B) immunoprecipitation assay. 
Park2 expression was detected by an anti-mouse light chain-specific antibody. * 





5.2.4 PARK2 serves as a novel E3 ligase for β-catenin 
  Having identified and confirmed the physical interaction, we next examined 
whether PARK2 promotes the ubiquitination of β-catenin. Importantly, 
exogenous expression of PARK2 significantly enhanced the conjugation of wild 
type ubiquitin to endogenous β-catenin (Figure 5.13A), but it failed to conjugate 
the ubiquitinG76V mutant [171] to β-catenin (Figure 5.13A, lane 3). In contrast, 
silencing of endogenous PARK2 expression in HEK293 cells reduced β-catenin 
ubiquitination (Figure 5.13B). Ubiquitination assays were next performed with 
either wild type PARK2 or its inactive mutants, including loss-of-function 
mutants T173A, T240M, and P294S (Figure 5.13C), as well as a known ligase-
dead mutant C431S [12]. Notably, compared with wild type PARK2, all of the 
mutants showed markedly decreased activity in ubiquitinating β-catenin, 
suggesting that PARK2-dependent ubiquitination of β-catenin requires its E3 
ubiquitin ligase activity. To date, ubiquitination of K19 and K49 sites in β-catenin 
is known to be associated with proteasomal degradation. To determine which 
lysine residue is modified by PARK2, K19R, K49R, and K19R/K49R β-catenin 
mutants were constructed and examined. K49R mutation in β-catenin 
compromised the ubiquitination contributed by PARK2 overexpression (Figure 
5.14), suggesting that K49 in β-catenin is one of the lysine residues potentially 
modified by PARK2. Together, these data support a novel role of PARK2, 








Figure 5.13 PARK2 is a novel E3 ligase for β-catenin. A, HEK293T cells were 
transfected with indicated vectors for 24 hours, and subjected to IP analysis with 
β-catenin antibody. UbiquitinG76V mutant (deficient in conjugation) was used as a 
negative control. B, HEK293 cells were transfected with indicated siRNAs for 48 
hours, and followed by co-transfection of indicated vectors for 24 hours. After 
MG132 treatment, cells were subjected to IP by either HA (lanes 1, 2) or GFP 
(lanes 3, 4) antibodies. C, HEK293T cells were transfected with indicated vectors 
for 24 hours, and subjected to IP by GFP antibody. MG132 was added 4 hours 






Figure 5.14 K49 in β-catenin is one of the lysine residues for ubiquitin 
conjugation by PARK2. HEK293T cells were transfected with indicated vectors 
for 24 hours, and subjected to IP analysis with FLAG antibody. MG132 was 
added 4 hours before IP.  
 
Figure 5.15 PARK2 is induced by active Wnt-β-catenin signaling. (A-B), 
Western blot analysis of endogenous PARK2 expression in A172 (A) and 
HEK293 (B) after Wnt3a treatment. A172 cells were treated with either L-cell 
control medium (Control Medium) or Wnt3a-conditioned medium (Wnt3a-CM) 
for indicated time courses. HEK293 cells were stimulated with 10 ng/mL 
recombinant murine Wnt3a (rmWnt3a) for indicated durations. Level of long-
form PARK2 was quantified by ImageJ® and normalized to β-actin. C, A172 and 
HEK293 cells stably expressing either GFP or β-catenin S33Y mutant were 





5.2.5 PARK2 is induced by active Wnt-β-catenin signaling  
  Very interestingly, activation of Wnt-β-catenin signaling by either Wnt3a-
conditioned medium or recombinant Wnt3a ligand induced the expression of 
PARK2 protein in A172 and HEK293 cells (Figures 5.15A-B). Moreover, A172 
and HEK293 cells stably expressing constitutively active β-catenin (S33Y mutant) 
showed elevated expression of endogenous PARK2 (Figure 5.15C), indicating a 
possible feedback regulation between PARK2 and Wnt-β-catenin pathway.  
5.2.6 PARK2 inhibits glioblastoma cell growth partially through suppressing 
Wnt-β-catenin pathway 
  To examine the biologic relevance of Wnt-β-catenin pathway in this study, I first 
examined the cell viability after depleting β-catenin. Beta-catenin silencing 
resulted in marked growth retardation of GBM cells (Figure 5.16). 
Immunohistochemistry analysis found that β-catenin levels were significantly 
elevated in glioma samples and correlated positively with tumor grade (Figure 
5.17). Moreover, high β-catenin transcriptional levels were associated with poor 
disease-free survival (Figure 5.18A) and overall survival (Figure 5.18B) in glioma 
patients. These data collectively support that Wnt-β-catenin pathway is crucial for 
glioma tumorigenesis. 
  Based on the aforementioned negative regulation of Wnt-β-catenin pathway by 
PARK2, next question was whether PARK2 regulates glioblastoma cell growth 
through Wnt-β-catenin pathway. Rescue assays were performed in U87-P cells by 





mutant) [169, 172]. MTT assay showed that both wild type and Δ45 mutant β-
catenin could partially rescue the proliferation-suppressive phenotype of PARK2 
(Figures 5.19A-B). Further, both wild type and Δ45 mutant β-catenin fully 
restored the soft agar colony-forming ability of U87 cells in the presence of 
ectopic PARK2 (Figure 5.19C). Taken together, these data suggest that PARK2 
restrains GBM cell growth partially through inhibiting Wnt-β-catenin pathway. 
 
Figure 5.16 β-Catenin is required for GBM proliferation. GBM cells were 
transduced with lentiviral particles encoding either Control shRNA or shRNAs 
targeting β-catenin for 72-96 hours, and then subjected to Western blot analysis 
(A) and MTT assay (B). Data represent Mean ± SD. **, P < 0.01. 
 
Figure 5.17 Expression of β-catenin protein is elevated in gliomas and 
correlated positively with pathological grade. Immunohistochemistry analysis 
of β-catenin expression in glioma samples and adjacent normal tissues was shown. 






Figure 5.18 Elevated transcription of CTNNB1 is associated with poor 
survival of glioma patients. A, High CTNNB1 expression (mRNA expression z-
Scores (RNA Seq V2 RSEM) > Mean + 0.2SD, n=32) was associated with poor 
disease-free survival of primary GBM patients based on TCGA cohort. Low 
CTNNB1 group consisted of 276 patients. B, High CTNNB1 expression (fold 
change > 2, n=13) was associated with poor overall survival of all glioma patients 
based on Rembrandt dataset. Low CTNNB1 group consisted of 330 patients. 
 
Figure 5.19 Overexpression of β-catenin counteracts the glioma-suppressive 
phenotype caused by PARK2. U87 cells stably expressing either ectopic 
PARK2 or GFP (Control) were infected with lentiviral particles encoding either 
GFP, or V5-tagged β-catenin (WT or Δ45 mutant), and then subjected to (A) 
MTT proliferation assay, (B) Western blot assay, and (C) soft agar colony 
formation assay. Data represent Mean ± SD. n.s., not significant; **, P < 0.01. 






  Alterations in Wnt-β-catenin signaling have been implicated in gliomagenesis [6, 
173-177]. Here, this study observed that total β-catenin levels in primary glioma 
samples correlated both with the grade of tumor and the survival probability, and 
that β-catenin is required for glioma cell proliferation. Murine Park2 has been 
shown to reduce the steady state level of β-catenin in murine cell lines and protect 
murine dopaminergic neurons from excessive Wnt signaling [178]. In the current 
study, a conserved physical interaction was shown between PARK2 and β-catenin 
across different species, and PARK2 was identified further as a novel E3 ligase 
promoting β-catenin ubiquitination and turnover through proteasome pathway.  
  Of note, similar to SIAH1, another E3 ligase for β-catenin, PARK2-mediated β-
catenin degradation is independent of the conventional β-catenin degron [179, 
180]. The signals triggering the PARK2-β-catenin interaction and/or PARK2-
mediated β-catenin ubiquitination remain unclear. In murine cells, Apc appears to 
be required for Park2-β-catenin interaction. Therefore, loss of Apc protein is 
likely to abolish the effect of Park2 on β-catenin ubiquitination. However, the data 
from murine model with Park2+/-; Apc+/min background reported that hemizygous 
deletion of Park2 confers growth advantage to colon adenomas [60]. Two 
possible models might explain this observation. First, the wild type allele of Apc 
in Apc+/min may cooperate with Park2 to restrict the β-catenin activation. Once 
Park2 is hemizygously deleted, the intracellular level of Apc and Park2 might be 
insufficient to capture and degrade β-catenin. The second possibility could be that 





pathway activation. Murine model with Park2+/-; Apcf/f  background would be an 
ideal system to address this issue. The involvement of human APC protein in 
PARK2 and β-catenin binding remains to be studied. 
  PARK2 strongly suppressed the expression of canonical Wnt targets as well as 
the response to Wnt3a stimulation. Constitutive Wnt activation through 
overexpression of either wild type or mutant β-catenin abolished PARK2-induced 
growth inhibition, supporting the concept that PARK2 functions as an upstream 
modulator of Wnt-β-catenin pathway. Very interestingly, Wnt-β-catenin 
activation elevated PARK2 expression which in turn constrained both β-catenin 
protein levels and downstream signaling, suggesting a potential feedback 
regulation. More studies are required to characterize the regulation of PARK2 






Chapter 6                







  To date, genetic and functional studies have identified important signaling 
transductions in GBM including receptor tyrosine kinase and PI3K pathways [2, 
3]. EGFR activation through mutation, amplification, alternative splicing and 
genomic rearrangement occurs very frequently in GBM. The involvement of 
PARK2 in EGFR signaling pathway is poorly studied. 
  In this project, initial cDNA microarray analysis of U251 cells with PARK2 
overexpression indicated a significant alteration of ErbB/EGFR pathway. To 
explore the potential mechanism, both overexpression and loss-of-function studies 
of PARK2 were performed and their corresponding effects on EGFR signaling 
pathway were evaluated. PARK2 could reduce EGFR expression in GBM cells. 
The reverse association between PARK2 transcriptional level and EGFR protein 
level could also be observed in GBM samples. Further studies showed that 
PARK2 enhanced EGFR ubiquitination, and suppressed EGFR downstream 
signaling.  
6.2 Results 
6.2.1 EGFR pathway is important for glioblastoma growth  
  To examine the biologic relevance of EGFR pathway in GBM, shRNAs 
targeting EGFR and AKT1 were designed and tested in GBM cells. As expected, 
either EGFR or AKT1 silencing potently suppressed the growth of GBM cells 





survival in different cohorts of patients (Figures 6.2 A-B), suggesting that EGFR 
hyper-activation is a driver for GBM development. 
 
Figure 6.1 AKT1 and EGFR are required for GBM proliferation. GBM cells 
were transduced with lentiviral particles encoding either Control shRNA or 
shRNAs targeting (A-B) AKT1 or (C-D) EGFR for 72-96 hours, and then 
subjected to Western blot analysis and MTT assay. Data represent Mean ± SD. 
n.s., not significant; **, P < 0.01. 
 
Figure 6.2 EGFR amplification and high expression predicted poor survival 
of glioma patients. A, EGFR amplification (n=197) predicted poor overall 
survival of GBM patients based on TCGA cohort. No EGFR CNV group 
consisted of 194 patients. B, High EGFR (fold change > 10, n=131) expression 
was associated with poor overall survival of all glioma patients based on 






6.2.2 PARK2 reduces EGFR expression  
  The potential role of PARK2 in EGFR pathway was explored in this study. 
EGFR itself was found to be down-regulated in GBM cells following PARK2 
overexpression (Figure 6.3). Remarkably, knock-down of endogenous PARK2 by 
either shRNAs or siRNAs resulted in significant elevation of EGFR proteins 
(Figures 6.4 A-B). In addition, depletion of PARK2 significantly up-regulated the 
amount of EGFR mRNA (Figure 6.4 C), indicating that PARK2 also modulates 
the expression of EGFR through transcriptional regulation. However, as PARK2 
is not a well-established transcriptional factor, this transcriptional regulation is 
possibly indirect and needs further characterization. 
 
Figure 6.3 PARK2 overexpression suppresses EGFR and its downstream 
targets in GBM cells. GBM cells stably expressing either GFP control or PARK2 







Figure 6.4 Depletion of endogenous PARK2 induces EGFR expression. GBM 
cells were transfected with indicated siRNAs and subjected for (A) Western blot 
analysis and (C) qRT-PCR analysis. B, GBM cells stably expressing indicated 





6.2.3 PARK2 restrains EGFR downstream signaling activation  
  Next, the downstream signaling pathway of EGFR, in particular, AKT signaling 
and ERK signaling was examined. PARK2 suppressed the phosphorylation of 
AKT at Ser-473, as well as S6K at both Thr-421 and Ser-424 (Figure 6.3), 
demonstrating the decrease of AKT activity and its downstream signaling. To 
extend these findings, the effect of PARK2 on acute epidermal growth factor 
(EGF) stimulation was examined in both HEK293 cells and GBM cells. PARK2 
overexpression significantly mitigated the molecular events induced by EGF, as 
evidenced by reduced levels of phospho-EGFR, phospho-GSK3β, phospho-AKT 
and/or phospho-ERK1/2 (Figures 6.5A-B). In contrast, depletion of endogenous 
PARK2 in HEK293 cells and A172 GBM cells augmented the cellular responses 
to EGF treatment (Figures 6.5 C-D). In further support of these results, in silico 
analysis showed that both total EGFR protein and phospho-EGFR levels were 
negatively correlated with PARK2 mRNA expression in GBM primary samples 
(Figure 6.6A-D). Together, these results indicate that PARK2 suppresses EGFR 
pathway. 
  Importantly, culture medium supplemented with EGF was able partially to 
restore the proliferation of PARK2-expressing GBM cells but showed no effect 
on control cells (Figure 6.7), suggesting that PARK2 regulates glioma cell growth 







Figure 6.5 PARK2 attenuates EGF-induced EGFR pathway activation. (A-B), 
Cells stably expressing either GFP control (C) or PARK2 (P) were serum-starved 
overnight and stimulated with EGF for indicated time courses. (C-D) Cells were 
transfected with indicated siRNAs for 48 hours, serum-starved overnight, and 
stimulated with EGF for indicated time courses. Working concentration of EGF 







Figure 6.6 Transcriptional levels of PARK2 correlate inversely with EGFR 
proteins in GBM samples. (A-D) Boxplots of reverse phase protein array (RPPA) 
data showing the positive correlation between the protein levels of PARK2 and 
EGFR/p-EGFR. GBM patients (TCGA, n = 542) without pretreatment were 
divided into PARK2 high (mRNA/miRNA expression Z-score ≥ Mean + 0.35SD) 
and PARK2 low (mRNA/miRNA expression Z-score < Mean + 0.35SD) group. 
 
Figure 6.7 Transcriptional level of PARK2 correlates inversely with EGFR 
proteins in GBM samples. MTT proliferation assay of U251 cells stably 
expressing either GFP control or PARK2 under either normal medium or 
conditioned medium supplemented with 200 ng/mL recombinant EGF. Data 
represent Mean ± SD. n.s., not significant; *, P < 0.05; **, P < 0.01. Values of 





6.2.4 PARK2 interacts with EGFR and promotes its ubiquitination 
  The molecular mechanisms by which PARK2 regulates the expression of EGFR 
were further explored. Co-IP assays showed that exogenous expressed PARK2 
interacted with EGFR, and the levels of EGFR ubiquitination were enhanced by 
PARK2 in the presence of either MG132 or EGF ligand (Figure 6.8A). However, 
only wild type PARK2, but not loss-of-function mutants (T173A, T240M, P294S 
and C431S), promoted the ubiquitination of EGFR in the presence of MG132 
(Figure 6.8B). PARK2 truncation mutants without RING2 domain (1-237 and 
E395X) also showed decreased ability to ubiquitinate EGFR, whereas the 
interaction between those mutants and EGFR could be maintained (Figure 6.8C). 
Those data suggest that PARK2 increases EGFR ubiquitination in an E3 ligase 
activity dependent manner, and that the N-terminus region (1-237 amino acid 
residues) of PARK2 might be responsible for PARK2-EGFR interaction. In 
addition to wild type full-length EGFR, PARK2 interacted with EGFRvIII and the 
intracellular domain (ICD) of EGFR (Figure 6.8D), suggesting the ICD may 
mediate PARK2-EGFR interaction.  
    Collectively, those data indicate that PARK interacts with EGFR, promotes its 







Figure 6.8 PARK2 interacts with EGFR, and enhances its ubiquitination. 
HEK293T cells were transfected with indicated vectors for 24 hours, and treated 
with (A-D) MG132 or (A) EGF before IP analysis with EGFP antibody. MG132 






  In this study, PARK2 was found to enhance EGFR ubiquitination, and potently 
suppress both EGFR expression and its downstream signaling.  
  The interaction between PARK and EGFR is likely to be mediated through the 
N-terminus of PARK2 protein and the intracellular domain (ICD) of EGFR. 
Surprisingly, PARK2 displayed great affinity to bind with EGFRvIII, the most 
frequent oncogenic variant of EGFR in GBM [181], as evidence by a more 
prominent enrichment of co-immunoprecipitated PARK2 in EGFRvIII group, 
when compared to either wild type EGFR or ICD group (Figure 6.8D). Notably, 
PARK2 overexpression accumulated appreciable amount of slow-mobility 
EGFRvIII in the present of MG132 (Figure 6.8D, Lane 3), suggesting that 
PARK2 may be a novel E3 ligase for EGFRvIII. EGFRvIII, is featured by an in-
frame deletion of 267 amino acids in the extracellular domain of EGFR, 
producing a mutant receptor that is deficient in ligand binding yet is constitutively 
active [182]. EGFRvIII has been shown to escape the c-Cbl mediated 
ubiquitination and exert great stability due to inefficient internalization and lack 
of effective ubiquitination [183]. Thus, PARK2 loss may amplify the EGFRvIII 
signaling in GBM cells. However, how PARK2-mediated EGFR ubiquitination 
would affect the EGFR and EGFRvIII turnover and the subsequent downstream 
signaling pathway activation awaits further characterization.    
  EGFRvIII has been characterized as a glioma tumor stem cell marker [184], and 





positive cells can be maintained under sphere culture and in xenograft tumors, but 
quickly lose the expression of EGFRvIII in adherent culture or after induction of 
differentiation through genomic alteration and epigenetic inactivation [190-192]. 
The biological evaluation of PARK2-EGFRvIII axis in GBM was hindered by the 
lack-of-expression of endogenous EGFRvIII in established GBM cell lines. 
During this study, efforts have been made to ectopically express EGFRvIII in 
established GBM cell lines, but EGFRvIII overexpression by lentiviral 
transduction in U87 cells triggered massive apoptosis (data not shown). 
Glioblastoma explant cell lines (e.g. GBM39) which are maintained routinely in 
stem cell culture condition [193] may serve as good model to examine the effect 
of PARK2 on EGFRvIII activity. 
  In support of the data in this study, Yeo et al. showed that ectopic expression of 
PARK2 in U87 cells inhibited AKT phosphorylation [63]. However, Lara Fallon 
et al. found that PARK2 promoted EGFR endocytosis, thereby promoting the 
EGFR-AKT signaling [146], which is disconcordant with our discoveries, 
suggesting that the regulation between PARK2 and EGFR-AKT is intricate and 
context-dependent. In addition to AKT and ERK signaling axes, EGFR and 
EGFRvIII orchestrate many intracellular signaling networks (e.g. STAT3/5 
pathway) and metabolism [185, 194]. Indeed, STAT3 protein level was found 
significantly down-regulated in U251-P and T98G-P cells (data not shown), 






Chapter 7                 
Therapeutic merit by dual targeting Wnt-β-catenin and 







  Both Wnt-β-catenin and EGFR pathways are crucial for glioblastoma 
tumorigenesis. Interestingly, stimulation or activation of EGFR has been reported 
to promote β-catenin transactivation [195, 196]; on the other hand, EGFR was 
shown to be a direct Wnt-β-catenin target gene in several cancer types [197-199]. 
The crosstalk between Wnt-β-catenin pathway and EGFR pathway in GBM needs 
to be addressed further.  
  Effective targeted therapies are in urgent need for clinical interventions of 
glioma patients. Because of their functional importance in cancer, Wnt-β-catenin 
and EGFR pathways serve as attractive targets for treatment [200, 201]. Many 
efforts have been made to block the Wnt-β-catenin pathway [202]. PKF-118-310 
is able to disrupt TCF4/β-catenin interaction [203]. ICG001, a CREBBP inhibitor, 
was identified selectively to block the interaction between β-catenin and its co-
activator CREBBP [204]. Meanwhile, EGFR inhibitors are under active 
development, but the use of several EGFR inhibitors was hindered due to either 
unresponsiveness, high toxicity or acquired resistance in GBM [193, 205-208]. As 
active EGFR transduces mainly through several key kinase cascades, targeting the 
downstream molecules (such like AKT or ERK) may be an alternative strategy to 
restrain the flux of EGFR pathway. Additionally, proper drug combination may 
improve further the clinical efficacy of EGFR pathway inhibition. Inspired by the 
newly identified tumor suppressive functions of PARK2, I tested and proved that 
combination of small-molecule inhibitors targeting both Wnt-β-catenin and 






7.2.1 Crosstalk between Wnt-β-catenin pathway and EGFR pathway   
  To explore the potential interplay between Wnt-β-catenin pathway and EGFR 
pathway, shRNA-mediated loss-of-function experiments were firstly conducted. 
shRNAs targeting EGFR powerfully silenced endogenous EGFR in U251 cells; 
and consequently, the phosphorylation level of AKT was decreased (Figure 7.1). 
Notably, the mobility of phospho-AKT protein was altered after EGFR depletion, 
suggesting a change in post-translational modifications of AKT in addition to the 
decrease of phospho-AKT at Ser473 site. Importantly, the β-catenin level was 
also markedly decreased in EGFR-depleted cells, suggesting that EGFR 
contributes to the maintenance of β-catenin protein in GBM cells. Similarly, 
shRNAs targeting β-catenin also effectively reduces the expression of both β-
catenin and EGFR proteins in A172 cells (Figure 7.1B). In parallel, the level of 
phospho-AKT at Ser473 was lowered, suggesting a decreased activity of the 
EGFR-AKT axis. Conversely, introducing either wild type or constitutively active 
mutant β-catenin into cells promoted EGFR expression (Figure 7.1C). Moreover, 
analysis of TCGA reverse phase protein array data further indicated a strong 
correlation between the expression of β-catenin and EGFR (Figures 7.2 A-D). 
Collectively, these results support the mutual enhancement of the Wnt-β-catenin 






Figure 7.1 Interplay between β-catenin and EGFR expression. (A-B) Western 
blot analysis of GBM cells transduced with lentiviral particles encoding either 
Control shRNA or shRNAs against (A) EGFR, (B) β-catenin. (C) Western blot 
analysis of A172 GBM cells and HEK293 cells stably expressing GFP, wild type  
(WT) or mutant (S33Y) β-catenin.  
 
Figure 7.2 β-Catenin correlates positively with EGFR proteins in GBM 
samples. GBM patients (TCGA, n = 542) without pretreatment were divided into 
β-catenin high (RPPA Z-score ≥ Mean + 0.25SD) and β-catenin low (RPPA Z-





7.2.2 Dual-targeting of Wnt-β-catenin pathway and EGFR pathway   
  Based on the above results, we tested targeting Wnt-β-catenin and/or EGFR-
AKT pathways by small-molecule inhibitors in glioma cells. First, the activities of 
two Wnt-β-catenin pathway inhibitors (ICG001 and PKF-118-310) and a pan-
AKT inhibitor (MK2206) were examined in HEK293 cells. As shown in Figure 
7.3, all three inhibitors reduced the AXIN2 protein level. Both ICG001 and 
MK2206 reduced the expression of phospho-S6K, and MK2206 dramatically 
diminished the expression of phospho-AKT. Next, the anti-glioma activities of 
those inhibitors were examined in six glioma cell lines. Similar to the results 
obtained by shRNA-mediated knockdown, these inhibitors potently suppressed 
glioma growth (Table 3.1). 
 
Figure 7.3 Effects of AKT and Wnt inhibitors on HEK293 cells. Western blot 
analysis of HEK293 cells in response to AKT inhibitor and Wnt inhibitors. Cells 
were treated with indicated inhibitors (1 μM) for 24 hours and then harvested for 





  As PARK2 showed robust anti-proliferative function through dual suppression 
of both Wnt-β-catenin and EGFR-AKT pathways, we hypothesized that 
combinational targeting of both pathways by small-molecule inhibitors might be 
synergistic. ICG001 and MK2206 were chosen as candidate molecules for 
combinational study, since they are well-tolerated as shown by multiple studies 
and/or clinical trials [204, 209] (www.clinicaltrials.gov). First, we determined the 
optimal combination ratio as 1:1 by checkerboard assay. With this ratio, 
combinational application of ICG001 and MK2206 markedly reduced each IC50 
(Table 3.1), and dramatically suppressed GBM cell proliferation at very low 
concentrations (Figures 7.4 A-B). Combinational Index analysis [210, 211] 
further confirmed the synergistic effect of the MK2206 and ICG001 combination 
in most GBM cell lines (Table 3.2). The markedly enhanced inhibitory effect of 
MK2206 and ICG001 combination was also evident by measuring the level of 
phospho-S6K which is the downstream target of AKT (Figure 7.4C). Collectively, 
these results suggest that dual-targeting of Wnt-β-catenin pathway and EGFR 
pathway could achieve synergistic anti-GBM effect. 
7.3 Discussion 
  GBM remains as one of the most aggressive human cancers with little advances 
for decades in either prognosis or therapy. This chapter provides a proof-of-
concept study for glioma treatment by dual targeting Wnt-β-catenin and EGFR-











Figure 7.4 Combinational use of MK2206 and ICG001 shows strong anti-
proliferation effect on GBM cells. A, Long-term proliferation assay of GBM 
cells under different drug treatments. T98G and U343 cells were treated with 
MK2206, ICG001 or the two drugs in combination (Com) at the doses of 2 μM 
(Low dose) and 4 μM (High dose). A172, U87, U138 and U251 cells were treated 
with MK2206, ICG001 or the two drugs in combination (Com) at the doses of 1 
μM (Low dose) and 2 μM (High dose). B, Crystal violet staining from (A) was 
dissolved by STOP solution and measured at OD 540 nm. In all cell lines, 
combinational treatment significantly decreased cell viability when compared 
with individual drugs (p < 0.01, One-way ANOVA). C, GBM cells were treated 
with indicated inhibitors (1 μM) for 24 hours and then harvested for Western blot 
analysis. 
 
Table 3.1  IC50 of AKT inhibitor and β-catenin inhibitors 
 
 
Table 3.2 Combination index values of MK2206 and ICG001 at IC50 
 
Values represent the combinational indexes (CI) of MK2206 and ICG001 
combination [210, 211]. Interpretation: additive effect (CI = 1), synergism (CI < 







  The positive correlation between EGFR and β-catenin expression was noted in 
primary GBM samples. Results based on cell line models also supported the 
notion that expression of EGFR and β-catenin is mutually dependent. Depletion 
of either protein resulted in the decrease of the other. The positive regulation of β-
catenin by EGFR might be through AKT-GSK3β axis, since AKT is able to 
phosphorylate and inactivate GSK3β which promotes the degradation of β-catenin 
[172, 212, 213]. As EGFR has been shown to be a Wnt-β-catenin target gene 
[197-199], the elevated expression of EGFR transcripts after PARK2 depletion 
(Figure 6.4C) might be due to increased β-catenin activity. As PARK2 inhibits 
both EGFR and β-catenin, its GBM-suppressive function is likely to be further 
amplified through the crosstalk between Wnt-β-catenin and EGFR pathways. 
  To test the effect small-molecule inhibitors targeting Wnt-β-catenin and EGFR 
pathway on GBM cells, EGFR inhibitors (Gefitinib and Erlotinib) and Wnt-β-
catenin pathway inhibitors (ICG001 and PKF-118-310) were firstly assayed 
during this study. Surprisingly, all the established GBM cells tested were very 
resistant to EGFR inhibitors (data not shown). Given that AKT is the key 
downstream molecule mediating the action of activated EGFR, targeting AKT 
instead of EGFR itself may be more effective. Thus, a pan-AKT inhibitor 
(MK2206) was employed. The IC50s of ICG001 and MK2206 were between 1 
μM to 13 μM, while PKF-118-310 showed a relatively higher potency. We 
observed that PKF-118-310 and ICG001 showed different effects on p-S6K level 
in HEK293 cells. Both inhibitors have been shown to inhibit β-catenin/TCF 





ICG001 but not PKF-118-310 can inhibit Myc expression). Since Myc is well-
known to regulate mTOR-mediated translation, the differential effects of PKF-
118-310 and ICG001 on p-S6K (mTOR target) level may result from their 
differential inhibitory activities towards Myc expression. Since ICG001 and 
MK2206 have been shown to be well-tolerated in animal models and humans 
[204, 209], they were chosen as candidate compounds for further study. 
Considering that PARK2 potently suppressed gliomas through inhibiting both 
Wnt-β-catenin and EGFR-AKT pathways, multiple combinational experiments 
were conducted. Combined application of ICG001 and MK2206 showed a 
remarkable synergistic anti-glioma effect. Mechanistically, the synergisms may 
result from the aforementioned crosstalk between Wnt-β-catenin and EGFR-AKT 
pathways; and indeed, β-catenin was recently reported to confer resistance to 
AKT inhibition in colon cancers [214]. Given that both MK2206 and ICG001-
derivative have entered phase I/II clinical trials for other cancers, our preclinical 















  In summary, we show that somatic inactivation and under-expression of PARK2 
contribute to gliomagenesis, and that PARK2 expression is a novel biomarker for 
glioma prognosis. Through detailed mechanistic studies, we uncover PARK2 as 
an important suppressor of both Wnt-β-catenin and EGFR pathways (Figure 8.1). 
Together with the results that dual inhibition of Wnt-β-catenin and EGFR-AKT 
pathways synergistically killed glioma cells, this study elucidates a 
comprehensive network involving PARK2/Wnt-β-catenin/EGFR-AKT signaling, 
and provides a candidate therapeutic approach in clinical management of this 
deadly disease. 
 
Figure 8.1 A proposed model of the anti-glioma functions of PARK2. A, In 
glioma cells with PARK2 loss, cytosolic as well as nuclear β-catenin level is 
increased, hence enhancing the expression of Wnt target genes. Meanwhile, 
EGFR protein is accumulated and triggers the activation of AKT and other 
downstream targets. The co-activation of the EGFR pathway and Wnt-β-catenin 
pathway enforces glioma growth. B, After restoration of PARK expression in 
glioma cells, the activities of EGFR and Wnt-β-catenin pathways are restricted, as 
both EGFR and β-catenin are ubiquitinated and degraded by PARK2. 





8.1.1 PARK2 inactivation in glioma 
  In this study, our bioinformatical analysis further suggests that PARK2 is 
targeted by various genomic defects in human cancers, especially glioma. Pan-
cancer genomic analysis of PARK2 mutations reveals that over 15% of somatic 
mutations are deleterious to PARK function. Copy number loss of PARK2 is 
frequently observed, and is the leading cause of PARK2 loss in glioma. The 
frequency of PARK2 deletion increased 4-fold from lower grade glioma to GBM. 
Down-regulation of PARK2 transcriptional level in glioma samples can be 
observed in multiple independent cohorts of glioma patients. Using cell line 
models, protein level of PARK2 is either low or absent in GBM cell lines as 
compared to HEK293 cells.  
8.1.2 Regulation of PARK2 
  Expression of PARK2 has been shown to be modulated by N-myc, Max, p53 
and ATF4 [28-30], and various environmental stimuli and stresses [30-34]. In this 
study, we showed that PARK2 can be regulated by p53, β-catenin, as well as 
Wnt3a stimulation. PARK2 expression can be induced by p53 but not solely 
dependent on it. We also showed that activation of Wnt-β-catenin pathway was 
able to induce both long form and short form of PARK2 proteins.  
8.1.3 Prognostic value of PARK2 expression in glioma 
  For the first time, we report the prognostic value of PARK2 expression in 
various grades of glioma. Lower PARK2 expression was strongly associated with 





Viotti et al. recently reported that the protein level of PARK2 was inversely 
correlated with glioma grade [69], which is in line with our observations that 
PARK2 expression is lost during glioma progression. 
8.1.4 Glioma-suppressive properties of PARK2 
  Expression of ectopic PARK2 suppressed GBM cell proliferation and 
anchorage-independent growth in vitro, while depletion of endogenous PARK2 in 
glioma cells promotes cell growth. Restoration of PARK2 in PARK2-deficient 
GBM cells substantially delayed tumor progression in immunocompromised mice 
and reduced the tumor burden. Moreover, PARK2 inhibits the migratory ability of 
GBM cells. 
  Based on our pan-cancer genomic analysis of PARK2 mutations, about 15% of 
those mutations lead to detrimental frameshifts, missplicings or pre-mature 
truncation of the PARK2 protein. Among non-synonymous mutations, T173A, 
T294M and P294S were shown to compromise the E3 ligase activity of PARK2 
yet retain the substrate binding ability. Consequently, all three mutants lost 
growth-inhibitory effect on GBM cells. Thus, E3 ligase activity is required for the 
tumor-suppressive function of PARK2. 
8.1.5 Pathways affected by PARK2 
  Pathway enrichment analysis based on transcriptome profiling of PARK2-
overexpressing GBM cells revealed the significant alteration of pathways 
involving metabolism, focal adhesion, actin cytoskeleton, ErbB/EGFR signaling, 





  Our study mainly focuses on the function of PARK2 as an E3 ubiquitin ligase. 
We report that PARK2 physically interacts with both β-catenin and EGFR, and 
promotes their ubiquitination in an E3 ligase activity dependent manner. 
Moreover, PARK2 displayed higher binding affinity to constitutively active 
mutants of β-catenin and EGFRvIII than their wild type counterparts, respectively. 
The interaction between PARK2 and β-catenin is conserved in both mice and 
humans, irrespective of tissue origins. Apc is requried for Park2-β-catenin 
interaction in MEF cells. N-terminus of PARK2 and the intracellular domain of 
EGFR were sufficient for the interaction between PARK2 and EGFR. 
  PARK2 accelerates β-catenin turnover through the proteasome pathway. We 
further showed that PARK2 suppressed the intracellular level of β-catenin, as well 
as its downstream targets including Cyclin D1, TCF4 and c-Myc. Regarding 
EGFR pathway, PARK2 is able to reduce EGFR expression at both the mRNA 
and protein levels. The downstream signaling of EGFR, including phospho-AKT, 
phospho-S6K and STAT3 could be inhibited by PARK2. Furthermore, PARK2 
attenuated the response of GBM cells to both Wnt3a and EGF stimulations. The 
growth retardation caused by ectopic PARK2 can be either fully or partially 
rescued by either β-catenin overexpression or EGF supplement. 
  Together, we show that PARK2 functions as a negative regulator of both Wnt-β-
catenin and EGFR signaling pathways. 





  Both Wnt-β-catenin and EGFR pathways are drivers for glioblastoma 
tumorigenesis, and emerge to be mutually dependent. The protein levels of β-
catenin and EGFR strongly correlated with each other in GBM samples. In cell 
line models, depletion of either protein resulted in the decrease of the other. 
Similar to PARK2, β-catenin and EGFR display strong prognostic values for 
glioma. β-Catenin protein was significantly elevated in glioma samples and 
correlated positively with tumor grade. High β-catenin transcripts predicted that 
both disease-free survival and overall survival of glioma patients would be poor. 
Amplification and high expression of EGFR also predicted poor survival of 
glioma patients. 
  We further show that the combination of small-molecule inhibitors targeting 
both Wnt-β-catenin and EGFR-AKT pathways could synergistically inhibit GBM 
cell growth. Combinational application of ICG001 and MK2206 markedly 
reduced IC50 of each other, and robustly suppressed S6K phosphorylation as well 
as GBM cell proliferation.  
8.2 Future perspectives 
  We and others have shown that PARK2 inactivation confers a growth advantage 
to human cancer cells both in vitro and in vivo [53, 54, 56, 60, 62, 63, 93]. Park2-
deficient mice are more susceptible to tumorigenesis [29, 60, 78], indicating its 
crucial role as a tumor suppressor. The tumor-suppressive function of PARK2 
may be achieved through multiple mechanisms. In this study, we have 
characterized the involvement of PARK2 in restricting both Wnt-β-catenin and 





8.2.1 Cancer metabolism 
  PARK2 has been shown to inhibit the Warburg effect [29]. Our cDNA 
microarray analysis revealed the significant alteration of the metabolic pathway 
by PARK2 (Figure 4.6). PARK2 may modulate the mitochondrial function and 
the expression/activity of key metabolic enzymes. Indeed, high prevalence of 
partial or total cristolysis (severe disruption of the inner mitochondrial membrane) 
was observed in astrocytoma and GBM mitochondria compared to control brain 
mitochondria [215-217]. Since PARK2 function is well-characterized in 
mitochondria homeostasis, PARK2 loss in GBM cells may impair mitochondrial 
turnover and function. Thus, the mitochondrial activity and ultrastructure of 
mitochondria need to be examined in GBM cells with and without PARK2 
expression. To investigate the effect of PARK2 on glioma metabolism, the levels 
of key metabolites (such like intracellular organic acids, free amino acids and 
lipids) should also be determined. Seahorse Metabolic Analyzers will be ideal to 
measure the oxygen consumption rate and extracellular acidification rate. 
Together, these future experiments will provide us with a comprehensive view of 
the role of PARK2 in glioma metabolism. 
8.2.2 TGF-β signaling pathway 
  Our data suggested that PARK2 significantly altered the expression of genes in 
the TGF-β signaling pathway. One hypothesis would be that PARK2 acts as an 
E3 ligase to regulate a key component in TGF-β pathway. Interestingly, a recent 





β receptor through binding to SMAD7-SMURF2 complex, leading to a 
strengthened TGF-β signaling activity [218]. USP15 antagonizes the PARK2-
mediated mitochondrial ubiquitination and mitophagy [219], but the question that 
whether the PARK2-counteracting effect of USP15 can be applied to other 
PARK2 substrates remains to be answered. Exploring the role of PARK2 in TGF-
β signaling will be an important part of future work. The interplay between USP 
15 and PARK2, and the effect of USP15 on non-mitochondria PARK2 substrates 
will also be examined. Given functional relevance of both USP15 and PARK2 in 
this pathway, TGF-β pathway may be the leading model to evaluate the USP15-
PARK2 interplay.   
8.2.3 Cell migration  
  The migration inhibitory activity of PARK2 has been observed in several cancer 
types, including GBM, ovarian cancer and breast cancer [62]. However, how 
PARK2 regulates cell migration is unclear. Notably, LIMK1 has been identified 
as an interacting partner of PARK2 [164]. LIMK1 phosphorylates and inactivates 
Cofilin, and regulates cell migration, invasion and cytoskeletal integrity [158-163]. 
PARK2 might enhance LIMK1 ubiquitination and reduce the level of LIMK1-
induced Cofilin phosphorylation [164]. Thus, the PARK2-LIMK1 regulatory axis 
may modulate cell migration.  
8.2.4 Activity and turnover of PARK2 
  The transcriptional and post-translational regulation of PARK2 in cancer is 





association between expression and/or activity of PARK2 and the cellular status 
of p53, N-myc and c-Abl in human malignancies, has not been determined. Our 
study also suggests the complicate feedback mechanism between PARK2 and 
Wnt-β-catenin or EGFR pathways. In addition, deciphering the functional 
importance of cancer-associated PARK2 mutations is a fertile ground of study. 
8.2.5 Cancer therapeutics 
  As an E3 ligase, the substrates of PARK2 involved in tumorigenesis remain 
largely unknown. Transcriptomic and proteomic approaches are required to 
profile systematically the targets of PARK2 in cancer. Understanding PARK2 
substrates and function will provide more insights into the development of cancer 
therapy by targeting PARK2 pathway. As an example, in this study, we 
discovered the role of PARK2 as a suppressor of both Wnt-β-catenin and EGFR 
pathways, and verified the synergistic effect of dual inhibition of Wnt-β-catenin 
and EGFR-AKT pathways in glioma cells. In addition, recent studies highlighted 
the PAK1/4-LIMK1-Cofilin axis as a promising therapeutic target in cancer. 
Considering the interplay between PARK2 and LIMK1, the contribution of 
PARK2 activity to either LIMK1 or PAK1/4 inhibitor sensitivity needs to be 
clarified. The theranostic application of PARK2 status in cancer could be further 
explored and developed. Also, generation of Park2 associated tumor models will 
be powerful tools to test the in vivo efficacy of small molecules modulating the 
PARK2 pathway, such as Vitamin K2 [220], leading to the development of 
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Appendix 1 PARK2 genomic defects identified in cancer cell lines 
PARK2 genomic defects identified in cancer cell lines 
Abbreviations: HD, homozygous deletion; HTD, heterozygous deletion; HM, 
homozygous mutation; HTM, heterozygous mutation. 
  
Cell line Tissue origin PARK2 defects 
CRL2020 brain HD  
Colo320 brain Multiple intragenic HTD 
T98G brain G1183T(E395X) HTM 
DLD1 colon C1237T(A379V); G1368A(R420H) HTM 
HT29 colon Chromosome 6 and 14 translocation 
LoVo colon C211T(P37L), -2A>G splice site HTM 
SW620 colon HTD 
Hep3B liver Exon 9 HTD; exon 5 heterozygous Duplication 
PLC5 liver Exon 3 HD; exon 4 HTD 
SK-Hep1 liver Exon 3 HTD 
SNU398 liver Exon 4 and 8 HTD 
Calu-3 lung Exon 2 HD 
H1573 lung Exon 2 HD 
H1975 lung G756T(Q252H) HM 
H23 lung G136A(A46T) HM 
HCC515 lung G983T(G328V) HM 
Ma10 lung Exon 6 duplication 
Ma29 lung Exon 3 and 4 HTD 
RERF-LCMS lung Exon 4 HTD 
VMRC-LCD lung Exon 5 and 6 HD 
OV177 ovary Exon 1 and 4 HTD 
OV202 ovary Exon 1 HRD 
OV207 ovary Exon 5, 8, and 12 heterozygous duplication 





Appendix 2 Links for databases and websites used in this study 
cBio Cancer Genomics Portal,  http://www.cbioportal.org/ 
CCLE, http://www.broadinstitute.org/ccle/home 
Clinical trials database, http://clinicaltrials.gov/ 
COSMIC, http://cancer.sanger.ac.uk/cosmic 
Integrated Genomics Viewer, http://www.broadinstitute.org/igv 
LOVD Database, http://grenada.lumc.nl/LOVD2/TPI/home.php 












Appendix 3 Summary of cancer-derived somatic PARK2 mutations 
Summary of cancer-derived somatic PARK2 mutations 




mutations Mutations (type of cancer) 
Mutations 
in PD 
2 I 12 1 I2V (glioblastoma)  7 F 100 1 F7L (pancreatic adenocarcinoma)  9 S 100 1 S9A (cervical cancer)  13 F 100 1 F13V (uterine corpus endometrioid carcinoma)  22 S 100 1 S22I (uterine corpus endometrioid carcinoma)  28 E 100 1 E28K (skin cutaneous melanoma)  37 P 69 1 P37L (colon cancer cell line, LoVo) P37L 
42 R 52 1 R42C (glioblastoma) R42P 
44 I 100 1 I44L (colon cancer)  46 A 100 3 A46E, A46T, A46T (lung cancer) A46P 
58 N 39 1 N58_splice (breast cancer) N58Qfs 
71 Q 15 1 Q71P (esophageal adenocarcinoma)  
80 M 18 1 M80I (head and neck squamous cell carcinoma)  
86 D 25 1 D86N (stomach adenocarcinoma) D86N 
88 P 31 1 P88L (skin cancer)  
92 A 11 1 A92fs (head and neck squamous cell carcinoma)  
95 C 10 1 C95S (lung cancer)  97 R 19 1 R97L (lung cancer)  
98 E 45 1 E98X (head and neck squamous cell carcinoma)  
113 P 71 1 P113S (lung cancer)  114 G 21 1 G114X (colon cancer)  129 K 30 1 K129N (colon cancer)  
138 A 45 2 A138_splice (lung cancer), A138P (lung cancer)  
145 S 100 1 S145N (skin cutaneous melanoma)  148 V 88 1 V148L (bladder urothelial carcinoma )  156 R 39 1 R156X (lung cancer)  158 Q 90 1 Q158H (lung cancer)  160 G 100 1 G160E (skin cutaneous melanoma)  
173 T 100 3 T173A (glioblastoma), T173M  (skin cutaneous melanoma), T173I (colon cancer)  
178 Q 74 1 Q178_splice (pancreatic adenocarcinoma)  179 G 100 1 G179_splice (lung cancer) G179Vfs 
186 V 100 1 V186I (lung cancer)  187 L 100 1 L187F (colon cancer)  200 H 31 1 H200P (lung cancer)  207 E 100 1 E207K (skin cutaneous melanoma)  209 F 65 1 F209L (colon cancer)  211 K 100 1 K211N (lung cancer) K211R/Asn 
213 G 68 1 G213V (lung cancer)  214 A 88 1 A214E (prostate cancer)  222 T 100 2 T222A (lung cancer), T222K (colon cancer)  
229 I 88 2 I229F (lung cancer), I229F (colon cancer cell line, HCT116)  
230 A 52 1 A230T (uterine corpus endometrioid carcinoma)  
232 N 100 1 N232H (colon cancer)  237 T 41 1 T237A (stomach adenocarcinoma)  
240 T 73 3 
T240M (pancreatic adenocarcinoma), T240M 
(stomach adenocarcinoma), T240M (head and 
neck squamous cell carcinoma) 
T240R/M 





275 R 100 3 R275P (lung cancer), R275Q (glioblastoma), R275W (melanoma) R275W 
279 H 56 1 H279P (lung cancer)  283 L 100 1 L283R (stomach adenocarcinoma)  
292 G 100 1 G292D (uterine corpus endometrioid carcinoma)  
294 P 100 3 
P294L (skin cutaneous melanoma), P294S 
(colon cancer), P294S (stomach 
adenocarcinoma)  
295 N 72 1 N295K (colon cancer)  298 I 100 1 I298F (stomach adenocarcinoma) I298S 
300 E 100 1 E300G (lung cancer)  307 L 100 1 L307M (colon cancer)  314 R 100 1 R314X (glioblastoma)  322 E 100 1 E322X (lung cancer)  324 V 100 1 V324F (breast cancer) V324Afs/Vfs 
326 Q 100 1 Q326H (prostate cancer)  328 G 100 1 G328V (lung cancer cell line, HCC515) G328Glu 
329 G 100 1 G329S (chondrosarcoma)  330 V 72 1 V330fs (colon cancer)  331 L 100 1 L331X (stomach adenocarcinoma)  335 P 100 1 P335L (skin cutaneous melanoma)  336 G 70 1 G336F (lung cancer)  
343 P 100 4 
P343L (cervical cancer), P343L (stomach 
adenocarcinoma), P343L (skin cutaneous 
melanoma),P343Q (lung cancer)  
344 E 62 1 E344G (glioblastoma)  346 D 27 1 D346N (lung cancer)  347 Q 51 2 Q347H (breast cancer), Q347H (lung cancer) Q347Qfs 
353 E 100 1 E353X (lung cancer)  354 G 26 1 G354R (lung cancer)  357 G 52 1 G357C (lung cancer)  
371 A 37 2 A371T (skin cutaneous melanoma), A371V (colon cancer)  
373 H 100 1 H373D (lung cancer)  378 S 37 1 S378G (skin cutaneous melanoma)  379 A 47 1 A379V (colon cancer cell line, DLD1)  394 D 83 1 D394G (stomach adenocarcinoma) D394Asn 
395 E 67 2 E395K (breast cancer), E395X (glioblastoma cell line, T98G)  
397 A 100 1 A397V (uterine corpus endometrioid carcinoma)  
398 A 100 1 A398T (colon cancer) A398T 
405 A 54 1 A405P (lung cancer)  407 S 89 1 S407C (colon cancer)  419 P 100 1 P419L (lung cancer)  
420 R 71 2 R420C (colon cancer), R420H (colon cancer cell line, DLD1)  
428 N 100 1 N428fs (colon cancer) N428Kfs 
429 G 100 1 G429_splice (lung cancer)  437 P 68 1 P437L (Low grade glioma) P437L 
449 C 56 1 C449F (lung cancer)  453 W 51 1 W453L (lung cancer) W453X 
458 M 89 2 M458I (lung cancer), M458L (bladder urothelial carcinoma )  
461 H 76 1 H461R (colon cancer)  464 D 75 1 D464N (glioblastoma)  
 
 
